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Marfan syndrome (MFS) is a systemic genetic disorder of the connective tissue that is 
inherited as an autosomal dominant trait with major manifestations in the ocular, skeletal and 
cardiovascular systems. The disease is caused by mutations in the fibrillin-1 (FBN1) gene 
which encodes a major extracellular matrix glycoprotein. Thoracic aortic aneurysms and 
dissections (TAAD) are the main cardiovascular feature in MFS that are associated with 
increasing mortality rate. Several other syndromic and non-syndromic overlapping diseases of 
MFS exists, including Loeys-Dietz syndrome (LDS), vascular type of Ehlers-Danlos 
syndrome (vEDS), arterial tortuosity syndrome (ATS) and bicuspid aortic valve (BAV) 
disease where the diagnosis is generally, successfully made using the current Ghent nosology 
criteria, but about 19% of the TAAD cases have a non-syndromic, familial TAAD (FTAAD). 
In worst case these subjects are diagnosed only in the medico-legal autopsies as they do not 
show outward phenotypic abnormality. Thus, a genetic test would be of benefit to improve the 
life quality of these subjects and to find close-relatives who may be at-risk of FTAAD. Until 
date, several genes are described to cause syndromic and non-syndromic TAAD, though an 
appropriate genetic test for their parallel testing is not yet available. Herein, we describe the 
novel 117-kb “MFSTAAD” with a custom duplicate resequencing assay that allows the 
coverage of all the exonic regions of eight candidate genes that are described in association 
with TAAD; FBN1, TGFBR1, TGFBR2, COL3A1, MYH11, ACTA2, SLC2A10 and NOTCH1. 
GSEQ and SeqC software were used for data analysis. The analytical sensitivity of the assay 
was validated by the recognition of 182 known mutations (153 point mutations, 21 deletions, 
7 insertions and 1 duplication) and a series of 66 unrelated individuals have been selected to 
determine the mutation yield, whereby 36 have been previously negative for mutations in the 
genes FBN1, TGFBR2 and a subset of 18 have been negative for an additional gene TGFBR1 





sensitivity for point mutations (100%) and the largest deletion of 16 bp was detectable 
through a decline in the hybridization strength. The overall analytical sensitivity was 85%. 
Mutation testing of 66 unrelated TAAD patients revealed 8 known and 13 possibly pathogenic 
mutations with a mutation yield of 33%. The MFSTAAD chip is an alternative tool to next 
generation sequencing that allows parallel analysis of several genes on a single platform. 
Refinements in the probe design and data analysis software will increase the analytical 
sensitivity of insertions and deletions making this assay even more applicable for clinical 
testing. Till date, follow up sequencing methodologies are performed to rule out large 
sequence alterations in patients negative for mutations using MFSTAAD resequencing assay 
such as MLPA, a-CGH followed by conventional Sanger sequencing technology. A total of 
three deletions in the FBN1 gene were found, a-CGH followed by PCR and bidirectional 
Sanger sequencing enabled the characterization of the extension of each deletion and the exact 
deletion breakpoints. Deletions included two large deletions: a 674.351 bp size deletion 
comprising of the complete FBN1 gene, and a total of five contiguous genes (DUT, SLC12A1, 
CTXN2, MYEF2 and SLC24A5) which were located 3’ of the FBN1 gene and a 256.593 bp 
size deletion consisting of exons 6 to 65 of the FBN1 gene and the contiguous DUT gene, and 
a small deletion of 9.134 bp consisting of 147 bp of exon 64, intron 64 and the complete exon 
65 and 3’UTR of the FBN1 gene and 7.484 bp of 3’ contiguous genomic sequence could be 
detected. Both, the novel “MFSTAAD” and follow-up analysis with MLPA have been good 
combination for the detection of all type of mutation described in TAAD. Additionally, an 
indirect genetic analysis was performed using polymorphic DNA markers for TAAD (AAT2 
on chromosome 5q 13-14; AAT1 marker on chromosome 11q23.2-24, TAAD3/BAV marker 
on chromosome 15q24-26 and TAAD/PDA, MYH11 on chromosome 16p12.12-13.13 and 
TAAD4, ACTA2 locus on chromosome 10q22-24) in two families who were negative for 
mutations using both aforementioned screening methods, but had a positive history for 





TAAD3/BAV marker and disease running in family 2 was found, but the disease gene for this 
marker remains still to be detected. On behalf of this thesis, specific histopathological medial 
alterations such as cystic medial necrosis (CMN) and elastin fragmentation (EF) in subjects 
with localized TAAD and age have been tested whether these factors were suggestive for a 
genetic predisposition to syndromic or familial TAAD. The correlation between both CMN 
and EF (value of ≥2) and age, independent from each other, versus mutation yield have been 
tested in a total of 18 decedents who have died of sudden and unexplained TAAD. No 
significant correlation was found between ≥2 alterations for CMN and EF versus patients with 
a mutation (p value 0.44). However, a relationship between TAAD occurring at young age 
(≤55.5 years of age) versus genetic changes could be observed, but the correlation was not 
significant (p value of 0.15). In summary, this study shows that “MFSTAAD” in combination 
with MLPA and indirect family segregation study will widen our understanding in the 
pathogenesis of TAAD and will definitely provide a rapid and accurate diagnosis, especially 
for patients who are at-risk for TAAD, but do not fulfil the clinical criteria for syndromic 
forms of TAAD, but show a familial segregation of TAAD. Even, when genetic testing cannot 
diagnose patients died of sudden TAAD, still close relatives could be helped with this 
approach, reducing the mortality rate associated with TAAD and improves their quality of 
life. 
 






Marfan-Syndrom (MFS) ist eine ganz-körper betroffende Erkrankung des generelisierten 
Bindegewebes, bei dem es sich um eine autosomal-dominante Vererbung handelt. Klinische 
Ausprägungen im Okular, Skelett und kardiovaskuläre System sind bekannt. Die Erkrankung 
wird durch Mutationen im Fibrillin-1 (FBN1) Gen verursacht, das sich im Genort 15q.21.1 
befindet. Dieses Gen kodiert für ein extrazelluläres Glykoprotein, dass ubiquitär exprimiert 
wird. Das Fibrillin- 1 Protein, polymerisiert sich in Mikrofibrillen, welches ein wichtiges 
Komponent des elastischen und nicht-elastischen Bindegewebes ist. Hohe Mortalitätsrate bei 
MFS Patienten ist primär assoziert mit der thorakalen Aorten Aneurysma und Dissektion 
(TAAD). Etliche syndromische und nicht-syndromische Marfan-ähnliche Form existieren, 
dazu gehört das Loeys-Dietz Syndrom (LDS), der vaskuläre Ehlers-Danlos Syndrom (vEDS) 
Typ, das Arterial- Tortuosity-Syndrom, genetische Ausprägung der bikuspidalen 
Aortenklappe, wobei die einzelne Fälle gemäß der Genter Nosologie erfolgreich diagnostiziert 
werden können. Es wird nur zu einem Problemfall, wenn Patienten keinerlei äußerliche 
klinische Ausprägungen aufweisen, sie werden nur diagnostiziert, wenn eine lebens-
bedrohende TAAD auftretet. Ungefähr 19% dieser Patienten haben mehrere erst-gradige 
Familienmitglieder, die ähnliche nicht-syndromische TAAD aufweisen, diese Patienten haben 
ein familiäres TAAD, bei dem die Erkrankung auch autosomal-dominant vererbt wird. Diese 
Studie sieht es als ein Vorteil genetische Untersuchungen auch bei unsicheren Fällen 
durchzuführen unabhängig von dem Ergebnis der Genter Nosologie. Bis zum Zeitpunkt der 
Studie waren acht Gene bekannt die Mutationen tragen, die Ursache eines syndromisches und 
nicht-syndromisches Marfan-ähnliches Syndrom zurück zu führen sind. Jedoch zur Zeit wird 
im genetischen Labor, Sanger Sequenzierung einzelner Gene durchgeführt, jenes sehr zeit-
und kostenaufwendig ist. Hier in dieser Studie, beschreiben wir „die 117-kb MFSTAAD“ 





(FBN1, TGFBR1, TGFBR2, COL3A1, MYH11, ACTA2, SLC2A10 und NOTCH1) parallel auf 
einem Platform zu analysieren. Die analytische Sensitivität des Assays wurde durch die 
richtige Detektion von 182 bekannte Mutationen (152 Punkt Mutationen, 21 Deletionen, 7 
Insertionen und 1 Duplikation) und die Mutationsausbeute wurde bei einer Reihe von 66 
nicht-verwandte Individuen untersucht, wobei 36 von den 66 Patienten wurden bereits auf die 
Gene FBN1 und TGFBR2, und 18 von den 36 Patienten auf ein weiteres Gen TGFBR1 mit 
dem koventionellen Sanger Sequenzierung in der Routine Diagnostik untersucht und waren 
negativ. Dieses Assay zeigte eine sehr hohe Sensitivität für Punkt Mutationen (100%) und die 
größte 16-bp Deletion wurde aufgrund eines stark abfallende Hybridisierungslinie detektiert. 
Im Großen und Ganzen hat dieses MFSTAAD Sequenzierungsplatform eine analytische 
Sensitivität von 85%. Mutation Analyse bei den 66 Patienten konnte 8 bereits bekannte und 
13 neue Mutationen aufgedeckt werden, was eine insgesamte Mutationsausbeute von 33% 
entspricht. Der MFSTAAD Platform ist eine gute alternative zum Next Generation 
Sequenzierung, der auch ermöglicht mehrere Gene parallel zu untersuchen. Spezielle 
Verfeinerung im 25-bp Oligonukleotide Design und im Auswertungsprogramm für die 
Detektion von große Genveränderungen könnte dieser Platform ohne Aufwand in der 
Routinediagnostik angewendet werden, jedoch zur Zeit ist dies ein Nachteil dieses Assays. In 
dieser Studie, wurde der MFSTAAD Platform mit zwei nachfolgende genetische Methoden 
kombiniert, Multiplex-ligation-probe-amplification (MLPA) und eine chipbasierte 
vergleichender genomischer Hybridisierung (Array-comparative genomic hybridization, a-
CGH). Insgesamt wurde mit der MLPA drei Deletionen im FBN1 Gen gefunden, und a-CGH 
und eine 3‘ und 5‘ gerichtete Polymerase Kettenreaktion wurde durchgeführt, um die exakte 
Bruchpunkte im FBN1 Gen zu definieren. Zwei große Deletionen: erste Deletion 674.351 bp 
groß, jenes das komplette FBN1 Gen umfasste  plus fünf benachbarte Gene (DUT, SLC12A1, 
CTXN2, MYEF2 und SLC24A5), die sich im 3‘ Ende auffand und eine zweite Deletion, 





eine kleine Deletion, die 9.134 bp lang ist, die 147 bp vom Exon 64, Intron 64 und das 
komplette Exon 65 und 3’UTR vom FBN1 Gen und 7.484 bp vom 3‘ Region des FBN1 Gens 
umfasste. Eine kombinierte Analyse mit dem neuen MFSTAAD Platform und MLPA und  a-
CGH,  erlaubte alle Mutationstypen in TAAD abzudecken. Als weitere genetische 
Untersuchung, wurde ein indirekter Gentest bei zwei nicht-verwandte Familien durchgeführt 
mit der Benutzung von kurze, nicht-kodierende DNA Markern die mit der TAAD Erkrankung 
(AAT2, 5q13-14; AAT1, 11q23.2-24; TAAD3/BAV, 15q24-26; MYH11, 16p12.12-13-13 und 
ACTA2, 10q22-24) assoziert waren. In Familie 1 wurde keine Korrelation zwischen den oben-
erwähnten TAAD Markern und der Erkrankung, die die Ursache in Familie 1 ist, festgestellt 
werden. Eine positive Korrelation zwischen TAAD3/BAV und die genetische Erkrankung in 
Familie 2 wurde gefunden, aber das Gen für diesem Marker bleibt bis heute unbekannt. Im 
weitere Interesse der Studie, wurden charakteristische histopathologische Merkmale wie z.B. 
Zystische Medial Necrosis (ZMN) und Elastin Fragmentation (EF) und das Alter als 
distinktive Merkmale für TAAD untersucht. Eine Korrelationsstudie zwischen ZMN und EF 
(Veränderungswert ≥2) und Mutationsausbeute wurde in 18 verstorbene Patienten 
durchgeführt, und eine statistisch signifikante Korrelation konnte zwischen diesen beiden 
Gruppen nicht festgelegt werden (p-Wert von 0.44). Jedoch ein Zusammenhang zwischen 
dem Alter (≤ 55.5 Jahren) und der Mutationsausbeute war zu sehen, aber war statisch nicht 
signifikant (p-Wert von 0.15). Im Großen und Ganzen kennzeichnet diese Studie, dass eine 
kombinierte genetische Analyse (MFSTAAD plus MLPA, a-CGH und indirekter Gentest) 
unser Verständnis über die Pathogenese der komplexen Erkrankung der TAAD erweitert.  
Eine genetische Untersuchung bzw. Beratung ist vorallem vorteilhaft, bei Patienten die nicht 
die klinische Bedingung der Genter Nosologie erfüllen und außerlich keine charakteristischen 
Merkmale eines oben-erwähnten Syndroms aufweisen, jedoch mehrere erst-gradige 
Familienmitglieder haben, die eine hohe Wahrscheinlichkeit für eine lebens-bedrohliche 
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1.1 Marfan syndrome 
Marfan syndrome (MFS, MIM 154700) is a multisystem genetic disorder of the connective 
tissue, with major involvement of the cardiovascular, ocular and skeletal systems and minor 
involvement of the skin and integument, lung and dura mater. The disorder was first described 
in 1896 by a French paediatrician, Antoine-Bernard Marfan. He described a 5 year old girl 
with apparent skeletal manifestation which he termed as hereditary disorder of the connective 
tissue (Marfan 1896; Loeys et al., 2010). The estimated prevalence of MFS is about 1 in 
10.000 with no difference among gender, ethnic and race (Pearson 2008; Faivre et al., 2007). 
The disease shows variable intra- and interfamilial phenotypic expression (Judge & Dietz, 
2005; William, et al, 2008; Ammash, et al, 2008). A clear familial cause of MFS has been 
described in about 75% of MFS cases (Yetman et al., 2003; Yuan & Jing, 2010), and the 
remaining 25% are sporadic (Keane & Pyeritz, 2008), caused by de novo mutations. 
 
1.1.1 Clinical characteristics of Marfan syndrome 
Patients with MFS are born with this condition, but the disease might not be diagnosed until 
later in life. Ocular sign include myopia, which is the most common ocular feature, and about 
60% of MFS patients manifest with ectopia lentis (EL, Figure 1-1, 1), which is the 
displacement of the lens from the centre of the pupil and are generally bilateral. These 
individuals are at highest risk of retinal detachment, glaucoma and early cataract formation. 
Skeletal manifestations are the predominant cardinal signs of MFS that gain the attention of a 
physician. The most obvious sign is the tall stature by which the lower segment of the body is 
greater than the upper segment, thin body habitus with an increase in the arm-span to height, 
which is fairly equal in the general population. Other obvious signs include joint hyper 
mobility with long, slender limbs known as dolichostenomelia and long, slender digits, 
termed as arachnodactyly. Both joint hyper mobility and long fingers allow the patient to 
fulfil two specific clinic criteria for MFS, such as the Steinberg thumb sign (Figure 1-1, 2), by 
which the entire thumb nail can protrude beyond the other side of the palm and the positive 
Walker-Murdoch sign (Figure 1-1, 3), where the thumb and the fifth finger can overlap 
around the wrist.  Furthermore, deformities of the chest caused by overgrowth of the ribs 
causing the chest to be pushed inwards, pectus excavatum (PE, Figure 1-1, 4) or outwards, 
pectus carinatum (PC, Figure 1-1, 5), and abnormal curving of the spine known as scoliosis 
(Yuan & Jing, 2010; Tsipouras & Silverman, 1999) are also frequently described in MFS. 





bones, and arched palate with crowded teeth. Cardiovascular symptoms are the most serious 
complications associated with morbidity and early mortality in MFS. Abnormalities include 
dilatation/aneurysm and dissection at the level of sinus of valsalva of the major aorta. The 
condition becomes fatal when the aneurysm reach an aortic diameter of >5cm (Karnath & 
Rangasetty, 2006) which may lead to dissection or rupture at the site of aortic aneurysm. The 
onset and progression of aortic disease is highly variable, but generally the severeness 
increase with age, but it is not uncommon in children (Sisk et al., 1983; Grimes et al., 2004). 
Mitral valve prolapse with/without regurgitation can also occur (Brown, et al., 1975).  










Figure 1-1:  Clinic characteristics of Marfan syndrome. 1, Ectopia lentis. 2, The positive 




















Figure 1-2: Anatomy of the major aorta. 1, Aortic root 2, Ascending aorta 3, Aortic 
arch 4, Descending aorta 5, Abdominal aorta. 
 
1.1.2 Classification of aortic aneurysms and dissections 
Aneurysms and dissections (AADs) are major diseases of the aorta and their severity are 
clinically classified in terms of their anatomical location using the DeBakey system (DeBakey 
et al, 1965) and Stanford classification (Daily et al, 1970). The DeBakey system defines the 
anatomical location of the primary intimal tear or where the dissection has initially occurred 
(Type I, II, III-Figure 1-3). Type I aortic intimal tear generally locates in the aortic root and 
intervenes into ascending aorta and aortic arch, and propagates further to the distally located 
descending aorta. This kind of dissections occur mainly in younger individuals (<65 years of 
age) (DeBakey et al, 1965). Type II dissections originate and remains in the ascending aorta 
and type III aortic dissections locate in the descending aorta, which rarely extend proximally, 
but can extend distally, this type of dissection are reported in elderly people who suffer from 
atherosclerosis or hypertension (DeBakey et al, 1965). Sixty-percent of patients with aortic 
dissections present with Type I dissections (aortic root, ascending aorta, aortic arch and 
descending aorta), about 10-15% present with type II dissections of the aorta (ascending 
aorta) and 25-30% have dissections of the descending aorta, type III aortic dissections (Figure 
1-2). The Stanford classification (type A and type B- Figure 1-3) are used in the clinical 
practice to determine whether dissection of the ascending aorta is involved or not, since 
ascending aortic dissections generally require surgical interventions (DeBakey System I and 
II), whereby dissections of the descending aorta (DeBakey system III) are generally managed 
with medical treatment (Daily et al, 1970). DeBakey type I and II and Stanford type A 















Figure 1-3: DeBakey system and Stanford classification. (Information has been derived 
from Wikipedia (http://en.wikipedia.org/wiki/Aortic_dissection#cite_note-Daily1970-6). The 
arrow (white) indicates the origin of the intimal tear in the aortic segment. Dark red represent 
the widening of an aneurysm in the appropriate aortic segment. 
 
1.1.3 Clinical diagnosis of Marfan syndrome 
The diagnosis of MFS occurs is based on clinical characteristic of three specific organ 
systems these include the systems of the cardiovascular, ocular and skeletal organs and the 
medical history of the patient’s family. MFS is a multisystem disorder of the connective 
tissue, and many of the clinical manifestations of the disease may occur in other heritable 
diseases. The current revised Ghent nosology criteria (Loeys et al, 2010) demonstrates the 
correct and efficient diagnois of MFS in the clinical setting which is based on the presence of 
major and minor clinical exhibition of the aforementioned organ systems (Table 1-1), the 
content in the table was partly adapted from Correlagen Diagnostics, Inc. 
(https://www.correlagen.com/fields/other/reviews/MFS_CRLGOvw.pdf- Marfan syndrome- 
an Overview) and from the Review by Canadas V, 2010. Cardinal manifestations include 
ectopia lentis, aortic root dilatation/dissection, dural ectasia or the presence of at least four 
skeletal features from the major criteria of MFS. The correct diagnosis of a MFS patient 
requires major involvement of at least two organ systems with minor involvement of a third 
organ system. Whereby, in the presence of a mutation in the FBN1 gene that is known to 
cause MFS or in the presence of a positive family history for MFS, in such case involvement 





make a diagnosis. Until date, the Ghent nosology has helped the clinician to diagnose MFS 
appropriately. Current molecular techniques allow the detection of causative mutations in the 
FBN1 gene in 75-93% of MFS patients who meet the Ghent nosology criteria (Loeys et al., 
2001; Loeys et al., 2004). Thus, the diagnostic criteria is highly specific, but the sensitivity of 
Ghent nosology criteria is rather complex, because the current criteria does not take into 
account the age-dependent manifestations of some clinical features, making the diagnosis of 
children more difficult (Faivre et al., 2009) and many of the clinical features seen in MFS 
patients overlap with other MFS-related connective tissue diseases. From the perspective of 
the differential diagnosis, a more stringent and modification in the current diagnostic criteria 
is required that implement clinical features of differential diseases of MFS which allow the 
accurate follow-up, and management guidelines for the various patient groups including 
children who do not yet meet the clinical criteria but may do in the future (Faivre et al., 2009). 
 
Table 1-1 Ghent nosology criteria for Diagnosis of Marfan Syndrome 
Minimal requirements of involvement of two major clinical criteria in two organ systems and one 
minor criteria in a third organ system 
Organ system Major criteria Minor criteria 




 Pectus carinatum 
 Pectus excavatum 
 Reduced upper to lower 
segment ratio or arm span 
to height ratio of >1.05 
 Wrist and thumb signs 
 Reduced extension at 
elbows (>170) 
 Scoliosis (>20) 
at least two manifestations listed under 
the major criteria, or involvement of one 
major and two of the following: 
 Pectus excavatum 
 Joint hyper mobility 
 Highly arched palate with 
crowding of teeth 









 Pes Planus 
 Protrusio acetabulae 
Ocular Ectopia lentis At least two of the following criteria: 
 Abnormally flat cornea 
 Increased axial length of the 
globe 
 Hypo plastic iris of hypo plastic 
ciliary muscle, causing decreased 
miosis 
Cardiovascular At least one of the following: 
 Dilatation of the ascending 
aorta involving the sinuses 
of valsalva 
 Dissection of the 
ascending aorta 
At least one of the following: 
 Mitral valve prolapse 
 Unexplained dilatation of the 
main pulmonary artery before age 
of 40 
 Calcification of mitral annulus 
before age of 40 
 Dilatation of dissection of 
descending thoracic or abdominal 
aorta before age of 50 
Nervous Lumbosacral dural ectasia  
Pulmonary  At least one of the following: 
 Spontaneous pneumothorax 







 At least one of the following: 
 Unexplained striae atrophicae 
 Recurrent or incisional hernia 
Genetics and 
Family History 
At least one of the following: 
 Mutations in the FBN1 
gene 
 First degree relative with 




1.4 Molecular genetics of MFS 
MFS is described as an autosomal dominant mendelian disorder characterized by complete 
penetrance with variable phenotypic expressions within and between families, which means 
that a person carrying the same mutation do not necessarily present with same clinical 
features (Judge & Dietz, 2005; William et al, 2008; Ammash et al, 2008). Classic MFS is 
generally caused by mutations in the fibrillin-1 (FBN1) gene, which is located on the 
chromosome 15 (15q21.1) (Ammash et al, 2008). Fibrillin-1 gene is composed of 65 exons 
and encodes a large cysteine rich 350kDa structural glycoprotein, a protein that consists of 
2871 amino acids. There are three types of fibrillins including fibrillin-1, fibrillin-2, and 
fibrillin-3. Fibrillin-2 and 3 are highly expressed in embryonic developmental stages, whereby 
fibrillin-1 is expressed from the gastrula stages throughout the adult life. Both founder 
proteins of fibrillins share an overall amino acid identity of 61%-69% with fibrillin-1. 
Fibrillin-1 is found in abundance in the extracellular matrix (ECM) and is important 
regulators of tissue development and homeostasis. Each fibrillin-1 construct polymerizes with 
each other to form a complex structure of 10nm-microfibrils. Fibrillin-rich microfibrils are 
found in a variety of connective tissues which are distributed as elastic (elastic fibres) and as 
non-elastic microfibrils. These fibrillin-elastic assemblies provide structural rigidity and 
elasticity to the tissues in combination with another ECM protein, collagen type III (Kielty et 
al., 2002; Ramirez & Dietz, 2007). Five distinct domains and a signal peptide are 
characteristic for a fibrillin-1 protein (Figure 1-5). The protein is primarily composed of 





times in fibrillin-1 protein. The EGF-like motifs contain about 45 amino acid residues and are 
arranged with six highly conserved cysteine residues that together form three disulphide 
bonds assembled in a specific order (C1-3, 2-4, and 5-6). Forty three of the 47 EGF-like 
motifs contain conserved calcium-binding sequences which are known as calcium-binding 
(cbEGF)-like motifs which are homologous to latent transforming growth factor binding 
protein (LTBP) which binds to TGF-ß protein (Robinson & Booms, 2001). To date, more 
than 2000 private mutations have been described which are distributed over the entire FBN1 
gene (Keane & Pyeritz, 2008; Ammash et al, 2008) which are registered in the UMD-FBN1 
database for MFS and its related heritable diseases. Mutations causing exon skipping have 
also been described in MFS (Collod-Beroud et al., 1998). Premature termination codon (PTC) 
mutations have been rather described in association with severe skeletal and skin 
manifestations (Faivre, et al., 2007). Boileau et al. described a large French family in year 
1991, representing with clinical features of both skeletal and cardiovascular system similar to 
those seen in MFS patients, but none of the family members have met the Ghent nosology 
criteria. The connective tissue disease in this family was also inherited in an autosomal 
dominant manner but no mutation in the FBN1 gene was found (Boileau et al., 1993). This 
condition was referred to as Marfan-like syndrome (Marfan type II, MIM #154705) and the 
gene harbouring mutations causing Marfan type II syndrome has been later mapped to 
chromosome 3 (3p24.2-25) (Collod et al., 1994). This new disease gene is TGFBR2 which 
encode the transforming growth factor beta receptor (TGFBR) type II. TGFBR is a 
heterodimeric protein composed of type I and II subunits encoded by TGFBR1 and TGFBR2 
genes, respectively (ten Dijke et al., 1996; Wrana et al., 1994). Both subunits of the TGF-ß 
receptor is composed of an extracellular domain, a transmembrane domain and a 
serine/threonine kinase domain. Another specific domain, a glycine/serine (GS)-rich domain 
include only for the TGFBR1. Signal transduction is initiated through the phosphorylation of 
the GS domain by the ligand-bound TGFBR2 (Wieser et al., 1995). Mutations in the TGFBR2 
gene have been described in the context of overlapping syndromes of MFS including Marfan 
type II syndrome, Loeys-Dietz syndrome (LDS) and in FTAAD. Majority of the TGFBR1 and 
2 mutations are missense single nucelotide variants which are generally found in the 
intracellular kinase domain which affect the receptor signalling. Histologic findings have 
shown a substantial overactivation of TGF-β (El-Hamamsy & Yacoub, 2009), but the true 
mechanism of an increased TGF-β signalling remains unclear. TGF-β is a cytokine protein 
which plays an important role in cell proliferation, differentiation, apoptosis and in 





Massague et al., 2000). During synthesis, TGF-β, the TGF-β1 form is released into the ECM 
where it is kept into its inactive state by a large complex protein known as latency-associated 
polypepetide (LAP) and latent TGF-β binding protein (LTBP) and microfibrils that are found 
in the ECM (El-Hamamsy & Yacoub, 2009; Gelb 2006; Chaudhri 2007). Once a stimulus is 
received, proteases release TGF-β1 from the protein complex, enabling its binding to their 
TGF-β receptors, initiating the process of signal transduction (El-Hamamsy & Yacoub, 2009). 
Due to the fact that microfibrils are made of fibrillin-1, and hence fibrillin-1 acts as a 
stabilizer of inactive TGF-β1-LTBP complex in the ECM, this could explain the relationship 
between abnormal TGF-β signalling and molecular pathogenesis of MFS and severe 
phenotypes seen in MFS. Since reduced or mutated form of fibrillin-1 may lead to failure of 
ECM sequestration of the TGF-β1-LTBP complex, leading to excessive TGF-β activation and 
signalling (El-Hamamsy & Yacoub, 2009). Interestingly, TGF-β missense mutations may 
manifest with loss of function and overactivation of TGF-β signalling as seen in MFS type II 
(Mizuguchi et al., 2004), LDS and TAAD, another overlapping disease of MFS. For instance, 
perturbation of the highly conserved amino acid residue at position 460 of TGFBR2 protein, a 
residue described to be important for structural integrity of the catalytic loop of the TGFBR2 
have been associated with loss-of-function of TGF-ß receptor 2 (Pannu et al., 2005), by 
contrast heterozygous mutations in LDS show an overactivation of the TGF-β signalling, thus 
bioavailability of one normal allele and one abnormal allele of TGFBR2 does not necessarily 
reflect the loss-of-function nature, it has been predicted that the overactivation may be a 
results of overactivation of wild-tpye TGF-ß receptor 2 to compensate for the loss of mutant 
allele (Loeys et al., 2005). 
 
1.2 Differential Diagnosis 
Some of the features and manifestations described in MFS are shared with several other 
diseases of the connective tissue (Table 1-2). Mutations in the FBN1 gene are also described 
in other genetic disorders which share distinct features of MFS which are termed as 
fibrillinopathies. The explicit overlap of their clinical features and in some extent the 
progressive nature of their manifestations, mainly the progressive dilatation of the aorta, 
render differential diagnosis a challenge, and a follow-up investigation and re-evaluation 
should be highly considered. Information on the main characteristic features of the different 
Marfan-related syndromes which should be taken into consideration during the differential 
diagnosis of MFS is summarized in Table 2 (Canadas et al., 2010) and in Table 1 (Loeys et 





overlapping clinical features with MSF where symptoms of all three organ systems (ocular, 
skeletal and cardiovascular system) and where defects in other genes are described. These 
include Loeys-Dietz syndrome (LDS), Bicuspid aortic valve (BAV) disease, familial thoracic 
aortic aneurysm and dissection (FTAAD), vascular form of Ehlers-Danlos syndrome (vEDS), 
arterial toruosity syndrome (ATS), ectopia lentis syndrome (ELS), Weil-Marchesani 
syndrome (WMS), Shprintzen-Goldberg syndrome, congenital contractural arachnodactyly, 
myopia, mitral valve prolapse, aortic root dilatation, skeletal and striae (MASS) disease and 
mitral valve prolapse syndrome (MVPS). 
Table 1-2 Differential diagnosis of Marfan syndrome 
Hereditary connective tissue disorders 
Fibrillinopathies 
 MASS phenotype 
 Ectopia lentis syndrome 
 Weil-Marchesani syndrome 
 Congenital contractual arachnodactyly 
 Shprintzen-Goldberg syndrome 
Non-fibrillinopathies 
 Ehlers-Danlos syndrome vascular type 
 Loeys-Dietz syndrome 
 Arterial tortuosity syndrome 
Non-syndromic familial aortic aneurysms 
 Bicuspid aortic valve disease 




 FBN1, LTBP2, ADAMTSL4 









 FBN1, ACTA2, MYH11, 
TGFBR1/2, AAT1, AAT2, 
TAAD/BAV 
 
1.2.1 Loeys-Dietz syndrome 
Loeys-Dietz syndrome (LDS) is an autosomal dominant disorder caused by mutations in the 
genes encoding two subunits 1 and 2 of the transforming growth factor beta receptor 





spaced eyes), bifid uvula/cleft palate, and/or arterial tortuosity with aortic aneurysm and/or 
dissection (AAD) (Loeys et al., 2005). Symptoms that distinguish LDS from MFS are 
craniosynostosis, Chiari malformation, clubfoot deformity, congenital heart disease, cervical 
spine instability, easy bruising and translucent skin. Importantly, the natural history of LDS 
patients is significantly worse in respect of cardiovascular complications than those with MFS 
or vEDS. In LDS, AAD often occur at younger age (mean age of 27 years) or at smaller 
dimensions (Judge et al., 2004). The progression of the vascular lesions is more widespread 
and not only confined to the major aorta (Finkbohner et al., 1995; Nollen et al., 2004). Other 
major cardiac symptoms include patent ductus arteriosus (PDA), BAV, mitral valve prolapse 
and atrial septal defect occurring at higher frequency than normal. Similar to MFS the disease 
expression can be highly variable within and between families. Abnormal long bone 
overgrowth is not always seen in LDS patients, although arachnodactyly may be observed 
which clinically overlap with MFS, in this case a molecular testing should be strongly 
considered for differentiation between these two disease groups. Patients who are positive for 
TGFBR1/2 mutations, but do not exhibit clinical features of LDS are designated as LDS2, and 
are thought to have a more aggressive vascular disease (Loeys et al., 2006; Mizuguchi et al., 
2004; Singh et al., 2006; Stheneur et al., 2008). 
 
1.2.2 Vascular form of Ehlers-Danlos syndrome (vEDS) 
The vascular type or type IV of Ehlers-Danlos syndrome is inherited in an autosomal 
dominant manner and is caused by mutations in COL3A1 gene which encode the protein type 
III collagen. The disease is clinically characterized by vascular and tissue fragility. Major 
symptoms that distinguish vEDS from MFS include translucent skin, easy bruising, 
dystrophic scarring, and they have a major risk for intestinal and uterine rupture. Typical 
AAD affect the medium sized arteries and about half of the AAD are confined to the thoracic 
or abdominal branch arteries (Pepin et al., 2000). 
 
1.2.3 Arterial Tortuosity Syndrome (ATS) 
Arterial tortuosity syndrome is another vascular autosomal recessive disease which is caused 
by mutations in the gene SLC2A10 that encode the protein, solute carrier family (facilitated 
glucose transporter), type 10 (GLUT10) leading to loss-of-function of the protein to express 
decorin, which acts as an important extracellular inhibitor of TGF-ß (Couke et al., 2006). 
Clinically, the disease is characterized by arterial tortuosity, stenosis, and AAD of the major 






1.2.4 Non-syndromic familial Thoracic aortic aneurysms and dissections  
Familial thoracic aortic aneurysms and dissections (FTAAD) is a major cardiac feature in 
MFS, but up to 19% of cases with TAAD do not meet the clinical criteria for MFS and have 
multiple close relatives with similar aortic disease indicating of a strong genetic 
predisposition (Biddinger et al., 1997; Milewicz et al., 1998). This condition is known as non-
syndromic form of TAAD, or familial TAAD (FTAAD). FTAAD is an autosomal dominant 
disorder with marked variability in the age of onset and has a decreased penetrance which 
makes the early identification of these affected individuals difficult (Francke et al., 1995). 
The condition is a genetically heterogeneous disease with three loci and four genes being 
identified so far including AAT1 at chromosome 11q23.3-q24, AAT2 at chromosome 5q13-
q14, TAAD3/BAV at chromosome 15q24-26, TGFBR2, MYH11, ACTA2 and FBN1 
(Vaugham et al., 2001; Zhu et al., 2006; Francke et al., 1995; Dietz et al., 1995; Hasham et 
al., 2003; Pannu et al., 2005; Guo et al., 2001; Avidan et al., 2010; Guo et al., 2007; Hoffjan 
et al., 2011). Pannu and colleagues reported mutations in the TGFBR2 gene in 4 unrelated 
families, showing only cardiac malformations (Pannu et al., 2005). Guo et al. reported a 
family in combination with or without livedo reticularis and iris flocculi caused by mutations 
in the smooth muscle alpha-actin (ACTA2) gene (Guo et al., 2007). TAAD in association with 
patent ductus arteriosus (PDA) was reported by Zhu and colleagues caused by mutations in 
the MYH11 gene. Aneurysms and dissections in these patients were rather confined to 
intracranial arteries, TAAD were less common. Majority of the mutations affect the C-
terminal coiled-coil segment of the smooth muscle heavy chain, a contractile protein of the 
smooth muscle cells. Studies have reported that heterozygous mutations in the MYH11 gene, 
lead to early and severe decrease in the elasticity of the aortic wall, leading to impairment of 
aortic compliance even with normal aortic size (De Backer et al., 2009). 
 
1.2.5 Thoracic aortic aneurysms and dissections in conjunction with bicuspid aortic 
valve  
Bicuspid aortic valve (BAV) affects about 1-2% of the population and it can occur in 
association with TAAD (Mills et al., 1978). The condition results from cystic medial necrosis 
(CMN), aortic wall abnormality also described in MFS. Patients with BAV have an increased 
risk for AAD compared to those with normal aortic valves (de Sa et al., 1999; Fedak et al., 
2002). AAD in BAV patients generally locates in the ascending portion of the major aorta, not 





association with AAD is also seen in young children (Gurvit et al., 2004). Worth knowing, 
there is a progressive AAD development even after valve replacement, indicating that these 
patients require life-long follow up, in order to prevent severe lesions. Dietz and colleagues 
reported results of comprehensive family studies showing BAV in association with AAD, and 
they have reported a large number of cases where AAD occurred alone, indicating that BAV 
and AAD are a result of a single gene defect with variable expression. The condition of BAV 
in family is inherited as an autosomal dominant condition with reduced penetrance. The 
condition can be sporadic or familial with an estimated frequency of 9.1-17.1% in families 
(Huntington et al., 1997). 
 
1.3 Molecular pathogenesis of TAAD in MFS and MFS-related diseases 
TAAD has been defined as a degenerative process characterized by CMN and elastin 
fragmentation (EF) of unknown cause. The aortic wall is highly dynamic and has a tightly 
regulated structural composition. Maintenance of aortic wall homeostasis involve strictly 
regulated interactions between important structural proteins and specific regulatory pathways. 
The normal arterial wall is composed of three layers including intima, media and adventitia. 
Each of the layers are separated from each other by two thick layers of elastic fibres (Figure 
1-4). The thickness, cell composition and biological properties of the arterial wall do vary 
along the arterial tree. The main structural and functional property of the aortic wall is 
maintained by the components in the lamellar unit (Wolinsky & Glagov, 1967). Each lamellar 
unit is composed of a vascular smooth muscle cell (VSMC) which is located between two 
layers of elastic fibres, which is composed of microfribrils and proteoglycans that form the 
ECM. The lamellar unit contains both tensile strength and elastic properties, such that the 
aorta can withstand the high pressure exerted on the arterial wall and allowing the arterial wall 
to return back to its normal size. Interaction between proteins of both VSMC and ECM 
mediates various function of the major aorta, thus dysregulation of one or more of these may 
















Figure 1-4: Schematic representation of composition of the aortic medial wall. ECM is 
composed of elastin embedded in the fibrillin microfibril scaffold, orange asymmetric bars; 
fibrillins, brown aligned bars connected with each other that make up microfibrils; 
proteoglycans, green; collagen, blue rod like structure. VSMCs, vascular smooth muscle cells 
is composed of α-actin blue chain structure; β-myosin heavy chain (β-MHC) red chain 
structure. Black bars indicate communication between VSCM and ECM protein collagen 
through signalling cascades. 
 
1.3.1 VSMCs 
VSMC have both contractile and secretory properties, these are interspaced by thin opposite 
lying elastic fibres (Owens et al., 2004) (Figure 1-4). The contractile properties are 
maintained by the proper interaction between smooth muscle α-actin and β-myosin heavy 
chain (β-MHC). This actin-myosin complex is found in the cell cytoplasm and are linked to 
ECM proteins through other proteins such as talin, vinculin, α-actinin and filamin-A. Thus, a 
cell contraction is a highly organized process and all these proteins are important to maintain 
aortic wall homeostasis. In addition to contractile properties, VSMCs possess secretory 
characteristics which facilitate the synthesis and repair of various ECM proteins that maintain 
the structure of the aortic wall including collagen, elastin, fibrillin and fibulin. Mutations in 
the contractile proteins, mainly in smooth muscle cell-specific actin encoded by ACTA2 gene 
on chromosome 10q23-24 and β-MHC encoded by MHY11 gene on chromosome 16p12.2-





alignment, and abnormal synthesis and degradation of ECM proteins. These TAA 
malformations become evident in the histologic findings as loss of VSMCs and EF. Mutations 
in the genes MYH11 and ACTA2 cause FTAAD. 
 
1.3.2 Collagen 
Both the media and the adventitia are abundant in type I and type III collagen (Figure 1-4), 
and its function is to provide tensile strength and rigidity to the arterial wall (van der Rest & 
Garrone, 1991). Whereby, type IV collagens are highly enriched in the tunica intima where it 
mediates the interaction of endothelial cells to the components of the intima. In addition to its 
structural properties, this protein has functional characteristics and acts as a reservoir for 
several soluble proteins. Therefore, mutations in genes encoding for collagen fibers can lead 
to structural and functional abnormalities leading to TAAD formation. Mutations in COL3A1 
gene which encodes the protein type III collagen is a result of vEDS. 
 
1.3.3 Elastin 
Elastin is also an ECM protein which is found in abundance in the thoracic aorta (Parks et al., 
1993) (Figure 1-4), especially in the tunica media. This protein is synthesized by VSMCs 
during a mechanical movement such as stretch or pressure; it provides recoil properties to the 
arterial wall. Similar to other proteins, elastin has regulatory properties on the structural 
component of the arterial wall; it can directly interact with the VSMC and maintain cell 
proliferation and migration. Elastin fragmentation is not the cause of TAAD; instead it is the 
loss of functional properties of elastin, leading to abnormal VSMC proliferation. 
 
1.3.4 Fibrillin 
Fibrillins are extracellular microfibrils, which are also found in the tunica media which 
interact with several other ECM proteins such as elastin, collagen, fibronectin and vitronectin 
(Figure 1-4). Three isoforms of fibrillins exist, fibrillin-1, 2 and 3. Fibrillin-1 is a major 
structural component in the ECM and provides mechanical strength to the aortic wall. 
Additionally, this protein plays a role in the sequestration and regulation of growth factors 
such as TGF-β1 and it can also activate several signaling cascades through its RGD motif. 





1.4 Today’s conflict in clinical and molecular diagnosis of Marfan and Marfan-
related cardiovascular diseases 
TAAD occurring as a syndromic form as seen in MFS are generally diagnosed clinically 
using the Ghent nosology criteria because of the presence of skeletal abnormalities, but there 
are several cases of TAAD where TAAD are often asymptomatic until severe complications 
or sudden death occurs. In such situations, TAAD can only be diagnosed by careful 
monitoring of the phenotypic abnormalities, age of death and a family history, since these 
factors may help to decide whether it relates to a heritable disease of TAAD or not (Loeys et 
al., 2010; Ripperger et al., 2009; Klintschar et al., 2009). In cases where the deceased provide 
phenotypic features for MFS, the diagnosis can be made clinically. But about 19% of the 
TAAD are familial cases and have several relatives with similar aortic disease, where the 
disease expression and age of onset is highly variable. These cases may only be handled by 
offering a genetic counselling to the first-degree relatives to make them aware of potential 
heritable risk of MFS and FTAAD and to offer a molecular testing of all TAAD candidate 
genes. To date, molecular testing is performed with conventional Sanger sequencing which 
does not allow the testing of all candidate genes for TAAD in a single experiment, and 
analysing all candidate genes individually is too expensive and time consuming. Thus, there is 
a huge demand for a molecular technique which allows the parallel testing of multiple genes, 
and which is rapid, efficient and cost-effective in order to help the clinician to make an 
accurate and early diagnosis of TAAD in relatives at-risk who might also be predisposed to 
severe aortic complications (Bode-Jaenisch et al., 2012; Ripperger et al., 2009; Klintschar et 
al., 2009). 
 




2. Aim of this study 
The main intention of this study has been to provide clinicians with a range of appropriate 
genetic tools which are cost-effective and quick, and provide accurate results that help to 
identify patients with TAAD who do not fulfil the clinical criteria for MFS, but have a high 
risk for sudden TAAD, as seen in individuals with FTAAD. We herein, have developed a 
novel molecular platform, the “MFSTAAD resequencing microarray” which enables the 
mutation screening of a large panel of genes that have been described in the context of 
syndromic and non-syndromic familial TAAD in a single experimental run. The study will 
test its overall performance, its analytical sensitivity in case of how good the novel platform is 
to detect known and novel DNA variants and finally whether this technology could be used in 
the clinical setting as a pre-screening method when traditional clinical imaging techniques are 
negative and in patients who fulfil the clinical criteria for MFS, but do not harbour a mutation 
in the classically defected FBN1 gene. Finally, we test a best fitting combination of traditional 
genetic sequencing technologies which can be used in the clinic in combination with 
MFSTAAD resequencing assay to cover larger sequence aberrations. As further interest, we 
will test when a genetic testing should be highly considered in patients with non-syndromic 
TAAD, this was done firstly, by investigating the correlation between histopathological 
changes in the thoracic aorta and mutation yield in patients who died of sudden, unexplained 
TAAD and secondly, by examining the overall mutation yield between two different aged 
groups (≤ 55.5 years versus > 55.5 years).




3. Materials and Methods 
3.1 Chemicals and Reagents 
Table 3-1 Chemicals and Reagents 
Reagents Vendor 
1M Tris-HCL, pH 7.8 Sigma Aldrich, Hannover 
10x PCR Buffer II (Mg
2+
) Qiagen, Hilden  
1x TE Buffer (pH 8) Ambion, Life Technologies, 
Darmstadt  
20x SSPE (3M NaCl; 0.2M NaH2PO4, 0.02M EDTA) Cambrex, Wiesbaden 
5M TMAC Sigma Aldrich, Hannover 
5M NaCl, RNase-free, DNase-free Ambion, Life Technologies, 
Darmstadt 
5x Sequence Buffer Applied Biosystems, USA 
6x Gel Loading Dye Blue BioLabs, New England 




 garose Carl Roth, Karlsruhe 
Boracic Acid Merck Millipore, Darmstadt 
Chloroform J.T. Baker, Deventer, Netherlands 
Denhardt's Solution 50x Concentrate Sigma Aldrich, Hannover 
Destilled Water Invitrogen, Life Technologies, 
Darmstadt 
DMSO Sigma Aldrich, Hannover 
EDTA Merck, Darmstadt 
Ethanol Absolute J.T. Baker, Deventer, Netherlands 
Ethidium Bromide Sigma Aldrich, Hannover 
Formamide Applied Biosystems, USA 
HPLC Water J.T. Baker, Deventer, Netherlands 
HCL J.T. Baker, Deventer, Netherlands 
Isopropanol J.T. Baker, Deventer, Netherlands 
MES Hydrate Sigma-Aldrich, Hannover 
MES Sodium Salt Sigma-Aldrich, Hannover 




Molecular Biology Grade Water Cambrex, Wiesbaden 
Phenol Carl Roth, Karlsruhe 
Sephadex
® 
G-50 Sigma Aldrich, Hannover 
Sodium Acetate Merck, Darmstadt 
SYBR
®
 Gold Nucleic Acid Gel Stain Molecular Probes, Life 
technologies, Darmstadt 
Tween-20 (10 % solution) Pierce, Thermo Scientific, Bonn 
 
3.2 Biological Substances and Enzymes 
Table 3-2 Biological Substances and Enzymes 
Biological materials Vendor 
100 bp DNA Marker BioLabs, New England 
Anti-streptavidin antibody (goat), biotinylated Vector Labs, England 
DNA marker (50-2500 bp) Cambrex, Wiesbaden 
DNA Molecular Weight Marker IV Roche Applied Science, Mannheim 
DNTPs BioSciences, Amersham 










 Size Standard Applied Biosystems, USA 
Herring Sperm DNA Promega Corporation 
IQ-EX Control Primers (20µM) Affymetrix, UK 
IQ-EX Control Template (7.5 kb and 3.5 kb) Affymetrix, UK 
Long Range PCR Taq polymerase Qiagen, Hilden 
Proteinase K Merck Millipore, Darmstadt 
SAPE (Streptavidin R-phycoerythrin conjugate) Molecular Probes, Life 
Technologies, Darmstadt 
Short range PCR Taq polymerase (5 U/µL) Qiagen, Hilden 
 
3.3 Buffer and standard working solutions 
10x TBE Buffer    
 Mix 0.9M Tris-HCL with 0.9M BoracicAcid and 0.02M EDTA 
DNA Gel Electrophoresis (2% or 0.8% agarose gel)   
 100mL of 1x TBE Buffer 




2g agarose (for 2 % agarose gel electrophoresis) 0.8g agarose (for 0.8% agarose gel 
electrophoresis) 
Procedure: Dissolve either 2g or 0.8g of agarose with 100mL of 1x TE Buffer in a 
microwave for approx. 3 minutes. Let the solution cool down (hand-warm) before you 
add 15µL of Ethidium Bromide. Pour gently the mixture in to a gel form containing a 
16 or 21 well comb. 
Loading Buffer 
 15mL Glycerin, 87%, 28.5 mL HPLC water one small spatula of Bromphen blue, one 
small spatula of Xylencyanoblue, mix well. 
Lysis Buffer 
 50mM Tris, 100mM EDTA, 0.5% (w/v) SDS set to a pH of 8.0. 
3.4 Kits and protocols 
Table 3-3 Kits and protocols 
Kit Vendor 
244K Agilent Human Genome e-microarray Agilent Technologies, Santa 
Clara, CA, USA 
BigDye Terminator Cycle Sequencing Kit Version 1.1 Kit: Applied Biosystems, USA 
DNA extraction Kit Qiagen, Hilden 
DyeEx 2.0 Spin Kit Qiagen, Hilden 
Expand Long Range, dNTPack Roche, Mannheim 
ExoSAP-IT Kit Affymetrix, UK 
GeneChip Resequencing Assay Kit Affymetrix, UK 
GoTaq Flexi DNA polymerase Promega, Mannheim 
GFX PCR and DNA Gel Band purification kit Illustra GE Healthcare Life 
Sciences, Freiburg 
KOD XL DNA Polymerase Merck Millipore, Darmstadt 
Qiagen LongRange PCR Kit Qiagen, Hilden 
MRC-Holland-Salsa MLPA kit 
Syndrome-1(P065) Syndrome-2 (P066) 
MRC Holland, The 
Netherlands 
PCR Product Purification Kit  Qiagen, Hilden 
Quanti-iTTM PicoGreen
®
 dsDNA Assay kit Invitrogen, Life 
Technologies, Darmstadt 
GeneChip CustomSeq Resequencing Array protocol Affymetrix, UK 




3.5 Data Analysis Software and custom guide 
AGCC software       Affymetrix, UK 
GeneMapper        Applied Biosystems, USA 
GeneChip Sequence analysis software     Affymetrix, UK 
GeneChip CustomSeq Array design guide P/N 701263- 
revision 4        Affymetrix, UK 
Genomic Workbench software     Agilent Technologies,  
         Waldsbrom, Germany 
Feature extraction software      Agilent Technologies,  
         Waldsbrom, Germany 
Picogreen fluorescence quantification Magellan software V6.6, 
Tecan, Crailsheim 
Module SeqPilot, SeqC and SeqPatient JSI, Medical Systems, 
Germany 
3.6 Consumable Materials 






 96 Well Cell Culture 
Cluster Flat Bottom Plates with lid 
Sigma Aldrich, Hannover 
96-well PS Clear black TC plate, flat bottom Greiner bio-one, Frickenhausen 
Combi Tips 0.5 and 5.0Ml Eppendorf, Hamburg 
Microcon YM-30 filters Millipore, Bitterica, MA, USA 
Micro Tube 1.5mL Easy Cap  Sarstedt, Nümbrecht 
Multiply
®
-µL tip Pro-8-strip  Sarstedt, Nümbrecht 
Ultra Amp PCR Plates 96-well Sorenson Biosciences, USA 
Falcon Tubes  Greiner bio-one, Frickenhausen 
Biosphere Filter Tips (20, 100, 200, 1000, 
1250µL) 
Sarstedt, Nümbrecht 
Gel Casting System 11.14 Whatman, Germany 
Sterile Nitrile Powder-free gloves Kimberley-Clark, Mainz 
Disposable Bags Carl Roth, Karlsruhe 
Aluminium Foil NeoLab, Heidelberg 
Parafilm NeoLab, Heidelberg 




Petri Dish Becton Dickinson, Heidelberg 
Pipette Tips (20, 100, 200 and 1000µL Sarstedt, Nümbrecht 




routine pack disposable cuvettes 50-
2000µL 
Eppendorf, Hamburg 
96-well plates 0.45µM Hydrophilic Merck Millipore, Darmstadt 
Low Protein Binding Durapore Membrane Merck Millipore, Darmstadt 
 
3.7 Equipments 




3130xl Genetic Analyzer Applied Biosystems, USA 
BioPhotometer plus Eppendorf, Hamburg 
NanoPhotometer Eppendorf, Hamburg 
Centrifuge 5424 (for 96 well plates) Eppendorf, Hamburg 
Centrifuge 5810R (for 1.5-2.0 mL tubes) Eppendorf, Hamburg 
Centrifuge 3200 Eppendorf, Hamburg 
Cleanbench Heraeus Sepatech 
Fluorescent 96-well Plate Reader Tecan, Crailsheim 
Gel Electrophoresis Apparatus Horizon 11.14 Bethesda,Research Laboratories, Life 
Technologies, Darmstadt 
Incubator Heraeus Instruments 
Intelligent Heating Block Biometra, Göttingen 
Microwave Micromat. AEG, Germany 




Voltage Supplier, Power Pack 0-250V Biometra, Göttingen 
Weighing machine Sartorins 
Vortex-Gene2  Scientific Industries, USA 
Thermostat 5320 Eppendorf, Hamburg 
IKA-Vibro-Fix LabExchange, Burladingen 
PCR Thermal machines 




T-Professional Basic Gradient, T-
Professional, T3 and T3000 
Biometra, Göttingen 
Gel Visualization 
Bioprofil -Video System Vilber, Eberhardzell 
Thermal Paper Film Model K 65 HM Mitsubishi, Germany 
UV Transilluminator Bachofer, LabExchange, Burladingen 
Video Copy Processor Mitsubishi, Germany 
 
3.8 Candidate Gene Reference Accession IDs 
Table 3-6 Candidate genes 





actin, alpha 2, smooth muscle, aorta 102620 NM_001613.1 ENST00000224784 
collagen, type III, alpha 1 120180 NM_000090.3 ENST00000304636 
fibrillin 1 134797 NM_000138.3 ENST00000316623 
myosin, heavy chain 11 160745 NM_002474 ENST00000300036 
notch 1 190198 NM_017617.3 ENST00000277541 
smad type 3 603109 NM_5902.3 ENST00000327367 
solute carrier family 2, member 10 606145 NM_030777.3 ENST00000359271 
transforming growth factor, beta receptor 1 190181 NM_004612.2 ENST00000374994 
transforming growth factor, beta receptor 2 190182 NM_003242.5 ENST00000295754 
 
3.9 In silico programs and commercial Database 
Amino Acid Alignment   http://www.ebi.ac.uk/Tools/msa/clustalw2/ 
Chi-Square Test    http://vassarstats.net/tab2x2.html 
Ensembl Genome Browser   http://www.ensembl.org/index.html 
Fisher's Exact Test    http://vassarstats.net/tab2x2.html 
FruitFly     http://www.fruitfly.org 
HGMD Mutation database   http://www.hgmd.cf.ac.uk 
Mutation Taster    http://mutationtaster.org 
NCBI Public Database   http://www.ncbi.nlm.nih.gov/ 
NetGene2     http://www.cbs.dtu.dk/services/NetGene2/ 
PMut      http://mmb.pcb.ub.es/PMut/PMut.jsp 
PolyPhen2     http://genetics.bwh.harvard.edu/pph2/ 




Primer 3 design    http://frodo.wi.mit.edu/primer3/ 
Protein domains    http://pfam.sanger.ac.uk/ 
Repeat Masker  http://www.repeatmasker.org/x-
bin/webrepeatmasker 
SNPCheck3     http://ngrl.manchester.ac.uk/ 
      SNPCheckV3/snpcheck.htm 
UCSC Genome Browser   http://genome.ucsc.edu/cgi-bin/hgGateway 
UMD Mutation database   http://www.umd.be 
UniProt     http://www.uniprot.org 
UniSTS database    www.ncbi.nlm.gov/unists 
Wilson score method    http://faculty.vassar.edu/lowry/prop1.html 
 
3.10 Proband recruitment and group design for the validation of a novel large-scale 
sequencing microarray 
A total of 247 unrelated patients were recruited from the institution of Human Genetics, 
Medical School of Hannover and from the department of Human Genetics, Ruhr University 
Bochum and the Heart and Circulation Research, University of Witten/Herdecke. A total of 
181 probands were positive controls in this study that either had fulfilled the Ghent nosology 
criteria for classic MFS and had a mutation in the gene FBN1 or were positive for LDS with a 
mutation in the gene TGFBR1 or TGFBR2 or have been positive for isolated non-syndromic 
FTAAD with a mutation in the ACTA2 gene. The positive cohort represented a total of 182 
known disease causing mutations, which included 153 point mutations (missense, nonsense 
and splice site mutations), 21 deletions (size range: 1 bp-16 bp), 7 insertions (size range: 1 
bp—3 bp) and a 15 bp duplication. Other 66 samples were composed of 36 retrospective and 
30 prospective samples (Figure 3-1). Retrospective living samples are denoted as “RL” and 
prospective samples are either denoted as “PL” (prospective living) and as “PD” (prospective 
decedent) in this study. To note, 20 out of the 30 prospective samples were recruited from the 
institute for Legal Medicine, Hannover. A medico-legal autopsy was conducted in all 20 
decedent, and histopathological examination of these decedents was performed in 18 
decedents by Bode-Jaenisch et al., 2012, except for one decedent, was examined in the 
intsitute for Pathology, Hannover. These different cohorts have been selected to design and 
validate a novel high-density oligonucleotide-based microarray. 










Figure 3-1: Division of 66 test samples. (A) Representation of apportion of 36 test 
probands between Hannover and Dortmund. Subjects in this group are suspected of MFS 
and/or LDS but are assigned negative for mutations in the genes FBN1, TGFBR1 and 
TGFBR2 using conventional Sanger sequencing reaction. (B) Representation of apportion of 
30 test prospective test samples. A total of 20 samples were recruited from the Legal 
Medicine, Medical School of Hannover who died of sudden, unexpected TAAD of unknown 
cause. The remainder of 10 was living subjects by whom TAAD was suspected without 
skeletal features suggestive for MFS. 
 
3.10.1 Probands selection for further studies 
Three unrelated subjects (designated as P1-P3) were recruited from the institute for Human 
Genetics, Hannover who had fulfilled the Ghent nosology criteria for MFS with 
manifestations in the skeletal, cardiovascular and ocular systems. Clinical profiles of two 
patients were collected from their medical records; please see Appendix 1 for references on 
clinical symptoms. Clinical history for one patient was not available. Routing molecular 
genetic testing of these individuals revealed no mutation in the genes FBN1, TGFBR1 and 
TGFBR2 using conventional Sanger sequencing reaction and multiplex-ligation-dependent 
probe amplification (MLPA). Final two individuals were subjects with several members in the 
family with skeletal features of MFS with or without TAAD. First subject was a patient from 
the institute for Human Genetics; Hannover (Appendix 2), the other patient was recruited 
from the department of Clinical Genetics, University of Regional Laboratories, in Lund, 
Sweden (Appendix 3). In an independent genetic study, Singh et al., 2012 identified two non-




synonymous DNA variants in exon 2 of the TGFBR3 gene (c.44 C>T, p.S15F and c.55 A>G, 
T19A) in family 1 (Appendix 2) and the variant c.55 A>G, T19A in family 2 (Appendix 3), 
which was found not to co-segregate with the disease in these two different families (Sing et 
al., 2012). In addition, during this study, the index patient in family 2 (Appendix 3) was 
further analyzed in the routine genetic testing and the colleagues from Lund detected a 
mutation in the ACTA2 gene (c.977 C>A, p.T326N), however, the mutation did not co-
segregate with the disease in family 2. 
 
3.11 Extraction of genomic DNA from whole blood and human tissue 
Extraction of genomic DNA from whole blood was performed using the QIAamp DNA Mini 
kit (Qiagen) under the instructions of the vendor. DNA extraction from human tissue such as 
aorta or spleen was extracted using the phenol-chloroform extraction technique. This method 
was first developed by (Chomczynski & Sacchi, 1987) and is used in the molecular biology 
for the fractionation of proteins and nucleic acids. In brief, a small portion (about 0.1-0.3g) of 
human tissue was transferred into a 1.5mL safe lock tube containing 500µL of lysis buffer and 
35µL proteinase K. The complete extraction was incubated in a compensator overnight at 
56ºC. Next day, equal volume of 500µL of phenol (pH of 8.0) was added to the extract. The 
mixture was vortexed for 2 minutes and centrifuged at 13000rpm for 10 minutes at 4ºC to 
enable phase fractionation. The aqueous phase or upper phase was cautiously transferred into 
a clean 1.5mL safe lock tube without transferring content from the interphase (white cloudy 
substance). As next step, 250µL of phenol and 250µL of chloroform were pipetted to the 
extract. The mixture was vortexed for 2 minutes and at 13000rpm for 10 minutes at 4ºC. The 
same procedure was repeated with equal volume of 500µL chloroform following the transfer 
of aqueous phase into a clean 1.5mL tube. A final volume of 0.2M of sodium acetate (3M) 
and 500µL of pure ethanol (96-100%) was added to the extract. The mixture was centrifuged 
at 13000rpm for 10 minutes at 4ºC. After the centrifugation step, the supernatant was gently 
discarded. The pellet on the bottom edge contain the genomic DNA which was purified with 
500µL of 70% ethanol and centrifuged at (13000rpm) for 10 minutes at 4ºC. This step was 
repeated twice. Following three purification steps with 70% ethanol, the DNA pellet was 
dried off at 37ºC and resuspended in at least 30µL of HPLC water which was dependent on 









3.12 Determination of genomic DNA concentration 
A spectrophotometer determines the concentration of a substance, as well as its purity in a 
mixture, by the simple measurement of the light absorbed by the components at a given 
wavelength. For instance, DNA itself, and most of their contaminants such as guanidium salts 
and phenol have absorbances in the region 230 to 320nm. Thus, the measurement of the 
absorbances in this region allows the measurement of DNA concentration and provides 
general information about the contaminant levels found in the mixture. Four important 
wavelengths are used for the measurement: 
 A230: light absorption by guanidium salts (allowed the DNA binding to silica 
columns in the DNA preparation) and phenol (used in phenol 
chloroform DNA extraction) 
 A260: light absorption by DNA 
 A280: light absorption by proteins such as tyrosine and tryptophan residues 
 A320: provides information on the general turbidity of the sample and is 
subtracted from the value for A260 
Nucleic acids such as dsDNA and ssRNA absorb UV light strongly at a wavelength of 260nm 
because of its nitrogenous base composition (A, G, C and T). At a wavelength of 260nm, the 
extinction coefficient for double stranded DNA is 0.020 per µg dsDNA per ml of solution per 
cm of light path, and for single stranded RNA it is 0.025 (µg/ml)
-1
1cm. Thus, an absorbance 
of 1 at 260nm in a 1cm quartz cuvette corresponds to 50µg/ml solution of double stranded 
DNA or 40µg/ml solution of a single stranded RNA. Based on this information, the following 
equation was used to calculate the DNA concentration: 
DNA concentration (µg/ml) = (A260 reading- A320 reading) x dilution factor (1/20) x 
  50µg/ml/1 
To evaluate the purity of DNA in the sample, the absorbances between 260nm to 320nm are 
used. The most common purity calculation is the ratio of the absorbance at 260nm divided by 
the reading at 280nm. Good quality of DNA should have an A260/A280 ratio between 1.7 -
2.0. Following the estimation of DNA concentration, a working solution of 10ng/µL was 
prepared for downstream applications. 
 
3.13 Separation of nucleic acids by agarose gel electrophoresis 
As confirmation, the yielded PCR products were separated according to their molecular 
weight and size by agarose gel electrophoresis. Agarose is a cross-linked polymer which is 
made up of disaccharide unit containing D-galactose and 3,6-anhydro-L-galactopyranose. 




Agarose in a gel acts as a matrix and is used in molecular biology for the separation of 
proteins and nucleic acids in size of >100 bp in an electrical field condition. Higher 
concentrations (e.g. 2%) of agarose were used for the separation of smaller DNA fragments 
(0.1-3 kb), while lower concentrations (e.g. 0.8%) of agarose were used for larger DNA 
fragments (0.4-19 kb). In order to follow the migration of nucleic acids during gel 
electrophoresis, special tracking dyes such as bromophenol blue and xylene cyanol dyes with 
similar migration rate of nucleic acids were used. The visualization of DNA fragments were 
enabled by staining the agarose gel with ethidium bromide during gel preparation. EtBr is a 
fluoroscent dye that intercalates into double stranded DNA and allows the visualization of 
DNA fragments under UV transilluminator. For the estimation of the size of the amplified 
fragments, molecular weight markers 1 kb plus (Figure 3-2a) DNA marker and DNA marker 









Figure 3-2a: 1 kb (plus) DNA marker. DNA marker used for smaller fragments under 








Figure 3-2b: DNA marker IV. DNA marker used for larger fragments using 0.8% agarose 
gel electrophoresis (http://www.roche-applied science.com/prod data/gpip/3_6_2_5_4_1.html, 
respectively). 




3.14 Short range Polymerase Chain Reaction 
For PCR reaction, primer pairs were designed using the online Primer3 input program and 
were checked for SNPs using SNPCheck3. The Polymerase Chain Reaction is used in 
molecular biology to generate millions of copies of a specific DNA fragment. This technique 
was developed in 1983 by (Kary et al., 1983) and relies on a thermal cycling condition, 
consisting of repeated heating and cooling cycles of the reaction for DNA denaturation and 
enzymatic amplification of the target DNA. It is called a chain reaction because the generated 
DNA fragments are re-used as a template for subsequent replication by which the DNA is 
exponentially amplified. Each cycle include three steps such as denaturation, annealing of 
primers and extension. Specific short primers (size range 20-27 bp) complementary to the 
target region and a heat stable DNA polymerase known as Taq polymerase, an enzyme 
isolated from the bacterium Thermus aquaticus are the key elements for a selective PCR 
product amplification. Herein, the Taq DNA polymerase from Qiagen was used and the assay 
was performed according to the instructions provided by the vendor. 
 
3.14.1 PCR Composition and Thermal Conditions of short range PCR 
Table 3-7: Reaction mix of one 25µL short range PCR reaction 
Component Volume in Each Reaction 
(µL) 
Final Concentration 
PCR Buffer 2.5 1x 
dNTPs 2.5 2mM 
Primer F 2 0.4µM 
Primer R 2 0.4µM 
Taq Polymerase 0.3 5U/µL 
Template 5 10ng/µL 
Q-solution 5 1x 









3.15 Conventional Sanger Sequencing Reaction 
Sanger sequencing is a DNA sequencing method and relies on the selective addition of 
specific chain-terminating di-deoxynucleotides which are incorporated by the DNA 
polymerase during in vitro DNA replication (Figure 3-2). This method was firstly developed 
by (Sanger, 1977) and was termed as “dideoxy” (dd) or “chain termination” method. A 
standard chain-termination method requires a single stranded DNA target template, a DNA 
primer (forward or reverse), a DNA polymerase, the four normal DNA building blocks 
(dATP, dCTP, dGTP and dTTP) and specific chain terminating nucleotides (dideoxyNTPs; 
ddATP, ddCTP, ddGTP and ddTTP). These ddNTPs lack a hydroxyl group (-OH) group 
which is required for the formation of a phosphodiester bond between two nucleotides, 
therefore it leads to chain termination when one of the ddNTPs is incorporated by the DNA 
polymerase during DNA extension process. Each of the ddNTPs is labeled with a different 
fluorescent dye to enable their detection. The incorporation of these ddNTPs takes place on a 
random basis, thus it leads to the generation of different sized fragments, but the ddNTPs 
incorporated in one sample remains the same for that position. In the past, DNA sequencing 
was performed in a four reaction tube by adding all the components listed above plus one of 
the ddNTPs. Following the DNA extension process, the resulted DNA fragments were 
denatured and separated by size using gel electrophoresis. The runs were visualized under UV 
light. The four reactions are run in parallel to allow the decoding of each DNA fragment. In 
this work, we used ddNTPs which have been labelled with a different fluorescent dye and 
workflow of a sequencing reaction is illustrated in Figure 3-3. The modification of these 
ddNTPs enabled the reaction to be done in a single reaction tube which saved time and 
expense. To decode each DNA sequence, we used the ABI Prism
TM 
3130 Genetic Analyzer 
which performs an automated size separation by capillary electrophoresis and detects each 
fragments through the fluorescently labeled ddNTP in each DNA strand. This fluorescence 
information was used by the software to unravel the DNA sequence and display the data as 
Table 3-8: Thermal Cycling Condition of short range PCR 
Initial Denaturation 95ºC 300s  
Denaturation 95ºC 30s  
Annealing 58ºC 30s 35 cycles 
Extension 72ºC 30s  
Final extension 72ºC 600s  
Holding 4ºC Indefinite  




fluorescent peak trace chromatogram. Sanger sequencing was performed in this study to 
confirm true positive mutations found with the MFSTAAD resequencing assay and for the 










Figure 3-3: Schematic diagram of conventional Sanger sequence reaction. First the two 
DNA strand are denatured. The primer binds to the target DNA. An enzyme known as DNA 
polymerase binds to the primer and starts copying the target DNA by incorporating free 
dNTPs that are complementary to the target DNA. The copying of the target DNA strand 
terminates following the incorporation of a fluorescently labeled ddNTP leading to copies of 
DNA fragments with varying size. These fragments with fluorescently labeled ddNTPs are 
then separated by size and are used to read out the original sequence order. 
3.15.1 Sequence Set Up and Thermal Cycling Condition 
Before the performance of Sanger sequence reaction assay, the PCR products were cleaned up 
using Exo-SAP-IT kit, the two enzymes contained in this kit enabled the removal of unbound 


























Table 3-9: Mix composition of one Exo-SAP-IT 
reaction 






Table 3-10 Thermal Cycling Condition of Exo-SAP-IT reaction 
 37ºC 20 minutes 
Enzyme inactivation 80ºC 30 minutes 
Addition of 10 µL HPLC water 
Table 3-11: Mix composition of a sequence reaction 
Components Volume in Each Reaction 
BigDye Terminator v1.1 1 µL 
BigDye Terminator 5x 
Sequencing Buffer 
1.5 µL 
Sequence primer  
(0.5 pmol/ µL) 
2.5 µL 
ExoSAP-IT clean up products 5 µL 
Table 3-12: Thermal Cycling Condition of a sequence reaction 
Initial Denaturation 95ºC 180s  
Denaturation 95ºC 20s  
Annealing 50ºC 30s 24 cycles 
Extension 60ºC 240s  
Holding 4ºC ∞  
Addition of 10 µL HPLC water 




3.16 Multiplex ligation-dependent probe amplification 
Multiplex ligation-dependent probe amplification (MLPA) was initially developed by 
(Schouten et al., 2002). It is a variant of multiplex polymerase chain reaction which allows 
the detection of abnormal copy numbers of a large number of different genomic DNA or RNA 
sequences (≤ 50 different copy numbers). MLPA allows the simultaneous analysis of about 96 
samples in a single experiment. Presence of partial gene deletions and duplications in most 
human heritable diseases range from 10% to 30% or even higher which can be covered by this 
method, thus increasing the overall mutation detections rate, and the molecular diagnosis of 
many genetic disorders (Aretz et al., 2007; Redeker et al., 2008; Kanno et al., 2007; Aldred et 
al., 2006; Kluwe et al., 2005; Michils et al., 2005; Furtado et al., 2011). MLPA has many 
advantages for the detection of copy numbers over many other techniques such as 
conventional sequencing and Denaturing-High-Performance-Liquid-Chromatography 
(DHPLC) which generally fail to detect copy number aberrations, and including southern 
blotting which fail to detect smaller copy number changes and are not favored in the routine 
diagnostics and array-Comparative Genomic Hybridization (a-CGH), another method that 
allows detection of copy number changes over the whole genome, but it is too expensive and 
technically far more complicated than MLPA. Although, well characterized gene deletions 
can be covered by conventional PCR reaction, but the exact deletion breakpoints remains 
unknown. Moreover, MLPA can be used on purified DNA. The major limitation of the assay 
is that it cannot be applied for genome-wide screening, but it is a good alternative to array-
based technique for many routine applications. Over 300 probe sets are now commercially 
available. The main principle of this assay is that it is not the sample DNA that is amplified 
during the PCR reaction, instead the MLPA probes that hybridize to the target sequence. The 
MLPA consists of four major experimental steps (Figure 3-3) these include: 
  1. DNA denaturation and hybridization 
  2. Ligation reaction 
  3. Exponential PCR amplification reaction 
  4. Separation of products by gel electrophoresis 
 
During the first step, the DNA is denatured and incubated overnight with a mixture of MLPA 
probes. Each of these probe consists of two oligonucleotides, containing a hybridization 
sequence (depicted in orange) and primer complementary sequence (forward primer (X) or 
reverse primer (Y), whereby only one of them contain different sized synthetic sequence 




known as stuffer sequence (depicted in green). Every probe set hybridize immediately 
adjacent to each other on their target DNA (Figure 3-4 step 1). Only hybridized 
oligonucleotides can be ligated during the ligation reaction (Step 2). Similarly, only ligated 
probes will be exponentially amplified during subsequent PCR reaction (Step 3). To enable 
the detection of each ligated probes and to distinguish the different samples, one of the 
universal primer pair is fluorescently labeled (Y-primer) and contain a universal sequence 
(depicted in green) which varies in size. The relative amount of each probe amplicons is a 
direct measurement for the relative quantity of probe-target sequence in the reaction sample. 
To quantify this relation, firstly, the relative signal of each ligated probe is compared to the 
signal of other ligated probes and then the final quantitation of the overall signals in the test 
sample are compared to the amount of probe-targets in the reference samples indicating which 
sequences show abnormal copy numbers. Normally, reference DNA samples are derived from 












Figure 3-4: The principle of MLPA. 
3.16.1 MLPA assay 
MLPA assay was only employed in PD1-20 and in patients P1-P3. We used the commercially 
available P065 and P06 MLPA kits containing probe mix for 54 exons of the 66 exons of the 
FBN1 gene and 7 exons of the TGFRB2 gene for the detection of copy number aberrations, 




such as deletions and duplication. The P065 and P066 did not contain probe mix for FBN1 
exons: 1, 11, 12, 21, 23, 28, 33, 38, 40, 49, 52, 60, and for TGFBR2 exon 2. DNA template 
for the MLPA assay was either derived from whole blood or human tissue using the QIAamp 
DNA Mini Kit and traditional phenol-chloroform extraction kit, respectively. The MLPA 
assay was performed according to the manufacturer`s instructions. In brief, for each reaction a 
set of 6 controls were added in each MLPA assay. Noteworthy, DNA from control samples 
were suggested to come from the same sample type. Two reactions were performed for each 
test and reference sample (with P065 probe mix and P066 probe mix). First 100ng of genomic 
DNA from whole blood and from human tissue was extracted and denatured for 10 minutes at 
98°C. A total of 3µL of probe mix were added. After brief incubation of 1 minute at 95°C, the 
probe mixture was allowed to hybridize to their target DNA overnight at 60°C in 8µL 
complete reaction. The ligation of the primers was performed for 15 minutes at 54°C after 
adding 32µL of ligase mix. The enzyme was then inactivated at 98°C for 5 minutes. As final 
step, the ligated MLPA probes were amplified using conventional PCR assay using FAM-
labeled universal primer pair. PCR protocol consisted of 1 cycle of 5 mins at 95ºC, 35 cycles 
of 30s at 95ºC, 30s at 60ºC and 30s at 72ºC, and a final extension cycle of 10 mins at 72ºC. 
Amplified PCR products from each run were visualized under UV light after gel 
electrophoresis and then injected into capillary electrophoresis on the ABI Prism
®
 3130xl 
Genetic Analyzer. The final fluorescence data of both reference and test samples were 
compared using sequence data analysis software module SeqMLPA. Deletions and 
duplications were assigned upon comparing the fluorescent peaks of the reference sample to 
that of the test sample. A duplication was confirmed when the peak fluorescence ratio was in 
the upper range (>100%) and a deletion when the peak fluorescence ratio was in the lower 
range (<100%). 
3.17 Refinement of deletion breakpoints using high resolution a-CGH and breakpoint 
spanning PCR  
a-CGH is a high-resolution molecular technique which was introduced by (Solinas-Toldo et 
al., 1997) to analyze copy number changes in tumour cells and is nowadays also used in the 
detection of genomic alterations in patients with mental retardation and congenital anomalies. 
The genome-wide resolution in detection losses and gains depends on the number of probes 
and the probe spacing. The 244K Agilent Human Genome Microarray contains a total of 
244.000 specific 60-mer probe species with a median overall probe spacing of about 7 kb. 
Herein, the Agilent e-array was used covering the chromosomal region of interest from 
46487797 MB to 46547591 MB covering the FBN1 gene with a probe spacing of 3 probes per 




1000 bp. The principle of assay is illustrated in Figure 3-5: test and reference genomic DNA 
samples are labeled with two different fluorophores, Cy3-UTP and Cy5-UTP, respectively. 
These dyes are incorporated into the corresponding gDNA using random primers and a 
mutant form of the Klenow fragment of DNA polymerase I (Exo-Klenow).  Labeled products 
were purified by Microcon YM-30 filters, pooled and hybridized together with 50μg of 
Human Cot I DNA at 65°C with 20rpm rotation for 40 hours. Washing steps were performed 
according to the Agilent protocol. Microarray slides were scanned immediately using an 
Agilent microarray scanner at a resolution of 2µm to measure the fluorescence intensities of 
each probe-target molecule. The normalized fluorescent ratio of each probe is then plotted 
against the chromosomal position. Gains or losses across the genome are identified by values 
increased or decreased from a 1:1 ratio. In a scan image the green fluorescence represents 
gain of one copy number and red represents loss of one copy number of test DNA for the 
corresponding target gene. Feature Extraction Software and Genomic Workbench software 






Figure 3-5: Array Comparative Genomic Hybridization. 
3.17.1 a-CGH assay  
In this study, two large deletions (exons 1-65 and exons 6-65) and one small deletion (exons 
64-65) of the FBN1 gene which were previously detected using the MLPA assay were 
analyzed with this assay in order to determine the extension of the three gene deletions in the 
3’ and/ or 5’ direction. The assay was performed with the help of Dr. Doris Steinemann, 
institute for Cell and Molecular Pathology, Medical School of Hannover following the 
instructions of the manufacturer. The final data of a-CGH was then used as a reference point 
to derive genomic sequence of three of 60-mer oligonucleotide probes from the UCSC 
genome browser. Two of which encompassing the deleted region in the 3’ and 5’ direction 




and one probe positioned on the suspected breaking site of the unique deletion by a-CGH. 
Probe sequences and their chromosomal locations are listed in tables in the appendix 
(Appendix tables 12-14). Information of each of these probe chromosomal location was used 
to design primer pairs for PCR amplification and conventional Sanger sequencing reaction 
which allowed determining the exact breakpoints. 
 
3.18 Linkage analysis using polymorphic microsatellite markers 
Microsatellites, also referred to as short tandem repeats (STRs) or variable number of tandem 
repeats (VNTRs), are short and simple segments of DNA consisting of two, three or four 
nucleotides, and can be repeated 3 to 100 times. The majority of these repeats occur 
predominantly in the non-coding regions, thus varying number of repeats has no influence on 
the gene function. Among these, (CA) n nucleotide repeats are the most frequently occurring 
microsatellites which account for 0.5% of the genome. The number of the repeats can vary 
between individuals that allows them to be used as genetic markers in the linkage analysis, 
genetic mapping and in the forensic science. 
 
3.18.1 Indirect DNA marker analysis in two German families 
In this work, DNA marker analysis was performed in two unrelated German families (P1 and 
P2). The first index patient I6 in family 1 (Appendix 2) was a female, with normal stature, 
but, multiple family members of this subject including her father, two of her brothers and her 
daughter showed a typical Marfan habitus, and one of her uncle from the paternal side died of 
abdominal aortic rupture at the age of 65 of unknown cause. Previous marker analysis with 
MFS markers revealed a disease association with markers for both TGFBR1 and TGFBR2 
genes, but no mutation could be determined in the Sanger sequencing reaction (data not 
shown). Furthermore, no mutations were detected in the index patient in the eight TAAD 
candidate genes (FBN1, TGFBR1, TGFBR2, COL3A1, ACTA2, MYH11, SLC2A10 and 
NOTCH1) using the novel MFSTAAD resequencing assay, these subjects were negative for 
mutations in SMAD3 gene using conventional Sanger sequencing and MLPA for large 
deletions and duplications for the genes FBN1 and TGFBR2. Another patient (P2) in family 2 
(Appendix 3) was a male with Marfan habitus and had an aortic aneurysm. Both his mother 
and uncle from the maternal side (Appendix 3, subjects 4 and 5) had a Marfan habitus, 
whereby aortic aneurysm was only reported in his uncle (Appendix 3, subject 5). The twin 
sister (Appendix 3, subject 2) of the patient’s mother died of an aortic rupture where the cause 
and age of presentation of aortic complication remained unknown. Routine genetic testing 




revealed a probably pathogenic mutation in the ACTA2 gene (c.977C>A, p.T326N), but did 
not co-segregate with the disease running in family 2 (Appendix 3). Due to the fact that the 
family history of both index patients (I6 and I9, respectively) correlate with the disease state 
of FTAAD, hence that FTAAD occurs without any syndromic features of MFS and MFS-
related syndromic diseases, and that FTAAD show a rather reduced penetrance and variable 
expressivity, we have recruited both healthy and suspected unhealthy family members of I6 
and I9 for a indirect DNA markers analysis with FTAAD loci. 
 
3.18.2 Marker selection 
To date, three causal loci AAT2 on chromosome 5q13-14 (Goe et al., 2001; Kakos et al., 
2003), AAT1 on chromosome 11q23-24 (Vaugham et al., 2001), TAAD3 locus on 
chromosome 15q24-26 in conjunction with bicuspid aortic valve disease; BAV (Goh et al., 
2002; Ellison et al., 2007) and two genes MYH11 mapping on chromosome 16p12.12-13-13 
in association with patent ductus arteriosus; PDA and ACTA2 mapping on chromosome 
10q22-24 (Guo et al., 2007) have been described for the heterogeneous disease TAAD. The 
haplotypes were ascertained by the number of repeats of each DNA marker. Three 
microsatellite markers located close to a candidate gene or a marker locus (Figure 3-6) were 
selected which consisted of variable number of dinucleotide CAn repeats representing with a 
high level of heterozygosity (>0.80). Their sequences were taken from previously published 


















Figure 3-6: Chromosomal position of DNA markers for loci linked with TAAD. Three 
candidate loci for TAAD; AAT1 locus (5q13-14), AAT2 locus (11q23-24) and TAAD3/BAV 
locus (15q24-26) and two candidate genes; MYH11 (TAAD/PDA locus) and ACTA2 (TAAD4 
locus) are indicated along with their chromosomal location. 
 
3.18.3 Testing and optimization of TAAD DNA markers for linkage analysis 
As initial step, primer pairs covering each DNA markers were tested for their optimum 
annealing temperature and the fragments were generated using short range PCR using DNA 
Taq polymerase. The PCR composition and thermal cycling conditions were the same as 
described in the section of short range PCR. Each of the STR markers was amplified using 6-
carboxyfluorescein fluorescently labeled forward primer and unlabeled reverse primer. The 
size of the microsatellite fragments ranged from 87 bp to 300 bp (Figure 3-7). Majority of the 
DNA markers were successfully generated under annealing temperature of 55°C, rest of the 
DNA amplicons were yielded at 51°C, 58°C and 61°C, respectively (Table 3-13). For marker 
linkage analysis, a total volume of 0.5µL of PCR product in respect of the band intensity 
(stronger band intensity: 0.5µL and weaker band intensity: 1.5µL) was added to the 
corresponding tube containing a cocktail of 0.5µL GeneScan
TM 
500 TAMRA size standard 




and 16 µL Hi-Di
TM
 Formamide. The complete mixture was then denatured for 3 minutes at 
95°C and immediately transferred on ice until loading into a genetic analyzer. 




51°C D5S626 (100), D11S924 (119) 
55°C D5S641 (265), D15S158 (81), D15S115 (115), D15S205 
(160), D10S1680 (217), D10S1739 (239), D16S3102 
(170), D16S3046 (102) 
58°C D16S3103 (233), D10S1765 (180) 









Figure 3-7: PCR products of DNA markers used in segregation analysis. Five controls 
(wells 1-5) were used for the optimization of DNA markers. (well 6) Blank. (M) 100 bp DNA 
markers, (1) D16S3046, (2) D15S205, (3) D15S115, (4) D5S641, (5) D15S158, (6) 
D16S3102, (7) D10S1739, (8) D10S1680, (9) D5S2029, (10) D11S4132, (11) D11S4195, 
(12) D5S626, (13) D163103, (14) D10S1765, (16) D5S2029. 
 
3.18.4 Sizing and Genotyping of DNA markers 
The fluorescence labeling of the forward primer and addition of GeneScan
TM
 500 TAMRA 
size standard in each sample allowed the detection and sizing of the fragments using ABI 




Prism 3130xl Genetic Analyzer. Both STR and sizing DNA molecules were injected 
electrokinetically into the capillary by applying a voltage to each sample. During 
electrophoresis, a high voltage of 15kV for 10 seconds was applied throughout the capillary 
that enabled the product separation by size based on their molecular charge. The complete 
fragment analysis was performed at 60°C to prevent the formation of DNA secondary 
structure (Wenz et al., 1998). Upon size separation, the fragments traveled through a detector 
window. Two colored system was used to label the products, the internal standard was labeled 
with a TAMRA fluorephore and the STR alleles with 5’FAM. To note, only the forward 
strands were incorporated with a fluorescent dye. Thus, under denaturing condition, the 
labeled forward strands were detected by exciting the dyes using a laser beam. The light 
emitted by each sample was detected using a CCD camera. Because each dye emitted light at 
a different wavelength (Table 3-14) when excited by a laser, all colors, and therefore 
fragments could be detected and distinguished between them. 
 
As part of the initial set of data, the light emitted by each fluorescently labeled fragment was 
interpreted by applying specific algorithms to the intensity in order to correct the spectral 
overlap between the dyes and the size of the fragments. After correction, the fluorescence 
intensities were displayed as peak in the electropherogram based on their color and size. 
GeneMapper analysis software was used to size and genotype unknown DNA fragments by 
using the standard curve (Figure 3-8) generated from the fluorescent intensity of the known 
fragments of the internal size standard. The internal size standard was labeled with a different 
colored dye so that it could be spectrally distinguished between DNA fragments of unknown 
size. Under denaturing condition, only the forward 16 labeled DNA fragments of the TAMRA 
size standard were detected by the genetic analyzer and the 16 different single fragments were 
displayed as electropherogram peaks (Figure 3-9). The fragment size ranged from 35 to 500 
bp. During genotyping analysis, it was made sure that every peak of the known size standard 
was detected and labeled correctly, before precise sizing and genotyping of each unknown 
DNA fragment. 
Table 3-14: Dye properties 
Fluorescence Dye Color Excitement maximum (nm) Emission maximum (nm) 
5’FAM blue 493 522 
TAMRA red 560 583 



















Figure 3-9: Fluorescence peaks of TAMRA 500 internal size standard. Size range: 35 
500 bp (35, 50, 75, 100, .139, 150, 160, 200, 250, 300, 340, 350, 400, 450, 490 and 500). 
Only one strand is labeled with fluorephore. Thus, the unlabeled strands do not interfere in the 
peak detection of the labeled fragments when run under denaturing condition. A corrected 
electropherogram with precise size of each sample was generated upon calibrating the 
fragment size and detection length between internal size standard and unknown DNA 
fragments. 
 
One peak allele was observed if a subject was homozygous (Figure 3-9, left) and two peak 
alleles if heterozygous (Figure 3-9, right) for a STR marker. The number of CAn repeats of a 
specific marker in each sample was determined by calculating the difference between the 
expected product size and CA repeats and the product size determined by GeneMapper. 
 












Figure 3-10: Electropherogram of a STR marker. One allele designates 
homozygous for marker xy and two alleles for heterozygous. 
 
How to calculate the number of CA repeats in a subject: 
Example: 275 bp (expected product size) - 273 bp (observed product size)  
= 2 bp (difference) 
This means 17 CA repeats in 275 bp and 16 CA repeats were contained in 273 bp. 
3.19 Custom-based high-density MFSTAAD resequencing microarray (Affymetrix) 
A novel large-scale microarray technology by Affymetrix allowed the parallel resequencing 
of multiple genes in a single experiment. The classical resequencing workflow includes eight 
major steps these include the selection of genomic target DNA, amplification of target 
sequence, quantitation and pooling, fragmentation and end-labelling, hybridization of target 
fragments to the array, washing steps and data analysis (Figure 3-11). Each step will be 
particularized in the next sections. A resequencing array consist of million copies of unique 
probe species, each containing of many copies of a 25 bp long probe of defined sequence. For 
each base interrogation, a total of eight probe species were required (four probes for each 
DNA strand; each of them were identical except for the middle nucleotide that was replaced 


































Figure 3-12: Array- based resequencing strategy. During hybridization, each base of the 
reference sequence (top row) is interrogated with one perfect match probe (bolded letter in 
highlighted in blue, left) and three mismatch probes. Four different 25-mer probes are 
required to resequence one base of a single stranded DNA; they are identical except for the 
central position where A, G, C or T is incorporated to enable efficient detection of all possible 
substitutions. Fluorescent signals of four probe species are depicted for each of the four 




interrogated bases (right panel) using sequence analysis software provided by Affymetrix 
which will be in later sections. Two fluorescent signals of similar intensity indicate a 
heterozygous change of base 3. 
 
3.19.1 MFSTAAD microarrays 
A total of 88 arrays were provided by Affymetrix for a 100-kb format microarray, 17 of these 
arrays were used for the validation of analytical sensitivity and its results reproducibility and 
the remaining 66 arrays were apportioned between two different laboratories, Hannover and 
Dortmund, 38 and 28 arrays, respectively (Figure 3-12). Initial steps including target selection 
and amplification, and quantitation, pooling and purification was performed in the main labs, 
pre-hybridization steps such as fragmentation and end-labelling of the DNA fragments and 
target hybridization to the array was solely performed in the department for Medical Genetics, 
MFT Services in Tübingen where the microarrays have been designed. Partial quantitation of 
PCR amplicons for 25 Hannover arrays were performed in CorTag, Dortmund, and the 
remainder were quantified in the institute of Immunology, MHH, Hannover, in order to 












Figure 3-13: Workflow of MFSTAAD resequencing microarray. 




3.19.2 Target sequence and probe selection 
A 100-format (117-kb) Affymetrix resequencing array platform was used to design and 
construct a customized resequencing chip, the MFSTAAD array. According to the custom 
array design guide, the sequences of interest of eight genes (FBN1 (fibrillin-1), TGFBR1 
(transforming growth factor, beta receptor 1), TGFBR2 (transforming growth factor, beta 
receptor 2), MYH11 (myosin, heavy chain 11), ACTA2 (actin, alpha 2, smooth muscle, aorta); 
COL3A1 (collagen, type III, alpha 1), SLC2A10 (solute carrier family 2, member 10) and 
NOTCH1 (notch 1) were identified and downloaded from the Ensembl database and 
converted into FASTA format and quality checked (Figure 3-11, step 1). Specific sequence 
regions such as repetitive elements, internal duplications that may have an impact of the 
hybridization process were checked using RepeatMasker. No repeats and internal duplications 
were found. The final reference sequences were then used for probe and primer selection. The 
sequences comprised of a total of 222 coding exons plus 43 bp of each flanking intronic 
region (each exon-intron boundaries) (Table 3-15), which included a total of 106.322 bp of 
target sequence. For the interrogation of each base of the target sequence a total of 425.288 
different probe species was synthesized on the array. The MFSTAAD array was a duplicate 
design, thus the 425.288 different probe species were synthesized on two defined field. As a 
positive control, the 7.5kb IQ-EX control template was used.  
 
3.19.3 Long range PCR assay 
Long range PCR assay has a high fidelity for the amplification of larger DNA fragments, 
which also reduces the number of PCR reaction when compared to conventional short range 
PCR methods. 
Table 3-15 Candidate genes of TAAD for array design 
Gene Number 
of exons 
Number of bases 
sequenced 




ACTA2 9 1993 15944 2 
COL3A1 51 8959 71672 5 
FBN1 65 14650 117200 17 
MYH11 41 9433 75464 12 
SLC2A10 5 2326 18608 3 
TGFBR1 9 2382 19056 3 





3.19.3.1 Testing of long range PCR assay kit 
Several long range PCR kits are available on the market, to get the best kit for this thesis 
work, several long range PCR kits (KOD-XL DNA polymerase (Novagen), Expand Long 
Range dNTPack (Roche), GoTaq Flexi DNA polymerase (Promega) and Qiagen LongRange 
(Qiagen)) were tested for their efficient and accurate amplification of 222 coding exons plus 
43 bases of each exon-intron boundaries covering all the genes FBN1, TGFBR1, TGFBR2, 
COL3A1, ACTA2, MYH11, SLC2A10 and NOTCH1 in order to get the best fit kit for 
MFSTAAD target DNA amplification (Figure 3-11, step 2). Primer sequences, composition 
and thermal cycling conditions of each long range PCR assay kits are listed in the appendix 
(Appendix 8-12). As preliminary testing, the 65 exonic regions of the FBN1 gene were used 
for the selection of a suitable kit which was cost-effective and required minimum optimization 
steps followed by the amplification of the exons of the remaining 7 genes. The correct 
composition of each target PCR was verified using bi-directional Sanger sequencing reaction. 
Two different size range and three different annealing temperatures for fragments < 8kb and > 
8kb were applied. To determine the efficacy of amplification long-range PCR enzyme, we 
used three controls. A total amount of 100ng genomic DNA have been used for the PCR assay 
and the final product sizes were in the range between 850 bp to 11.500 bp. 
 
3.19.4 PicoGreen quantification, pooling and purification of PCR amplicons 
Application of equimolar concentration of each target amplicons in the hybridization process 
was necessary in oder to get a good quality and reliable amount of sequence information from 
the MFSTAAD resequencing array 8Figure 3-11, step 2-3). For larger number of samples, the 
quantification of PCR amplicons was performed using the PicoGreen quantification method. 
The PicoGreen quantitation reagent is a ultra-sensitive fluorochrome that binds selectively to 
double-stranded (ds) DNA. This dye emits light at its maximum when it is chelated to 
dsDNA. Procedures on quantitation was performed according to the instructions by 
Affymetrix and the following worksheets were downloaded from Affymetrix homepage: 
 
TGFBR2 8 2708 21664 4 
NOTCH1 34 10710 85680 8 
Total 222 53161 425288 54 
plus 43 bp of each exon-intron boundary 




 PicoGreen Quantitation Protocol 
 PicoGreen Quantitation Raw Data 
 PicoGreen Quantitation Standard Curve 
 PicoGreen Quantitation PCR Product Pooling 
3.19.4.1 Quantitation and pooling of PCR amplicons 
Briefly, at first picogreen working solution was prepared and kept in the dark until use. The 
DNA standard curve was prepared by adding 3.84µL (100 ng/µL) of lambda DNA to 296.16 
µL of 1x TE buffer in a safe lock micro-centrifuge tube. The mixture was gently vortexed and 
centrifuged. The total mixture of 300µL was added to well C12 of a transparent 96-well plate. 
A two-fold serial dilution was made by transferring 150µL of DNA standard into each 
subsequent well until a concentration of 0.04ng/µL was reached (D12 to H12). The remaining 
wells were filled with 298µL of 1x TE buffer and 2µL of each PCR product was added to an 
empty well. The plate with the samples was shaken for 5 minutes at 900rpm and was gently 
centrifuged. A light protective 96-well plate was used for the DNA quantity measurement. 
100µL of PicoGreen was added to all wells that were required for the measurement and the 
wells C12-H12 was also filled with 100µL PicoGreen for the DNA standard curve. The 
fluorescence intensity of PicoGreen was measured using a microplate reader and the final data 
was extracted using a user specified method with Magellan data analysis software. 
Custom Settings for Magellan microplate reader: 
Wavelength   Excitation at 485nm 
    Emission at 535nm 
Reads    3 
Integration time  40µs 
Gain setting   manual 69 (any overflow should be diluted with TE and  
    the measurement has to be repeated for that particular  
    sample) 
At first, a blank reading was obtained. After blank reading, a total of 150µL of each sample 
was added into the corresponding wells containing PicoGreen and the measurement of the 
target samples was started. The raw data of blank and the raw data of the samples were 
entered in the appropriate worksheet (PG protocol) to generate a standard curve (Figure 3-14). 
The standard curve was used to calculate the amount of each DNA sample required for 
pooling. Equimolar amounts of each 54 PCR amplicons from each patients sample were 
pooled at a concentration of 150 picomolar per PCR fragment for a 100-array format. The 




amount of sample required from each amplicon was generated from the Affymetrix 
PicoGreen Quantitation worksheet. Pooled PCR products were then purified using QIAquick 









Figure 3-14: Standard curve of PicoGreen. The standard curve is automatically generated 
based on the values entered in the PG raw data input. The pooling of amplicons was continued 
when the standard curve was linear and the value for R
2 
was >0.9, the reading was repeated if 
the value of R
2
 was below 0.9. 
 
3.19.5 Fragmentation 
The samples were then subjected to DNA fragmentation (Figure 3-11, step 3) using 
fragmentation reagents from the Affymetrix resequencing assay kit. The set up of 
fragmentation reaction and the thermal condition for the fragmentation has employed as 




 Resequencing array protocol. The fragmentation 
reaction was performed in a reaction volume of 28µL at 37°C for 35 minutes with 0.015U of 
fragmentation DNAase enzyme per microgram DNA and was inactivated at 95°C for 15 
minutes. Successful fragmentation was checked on a 20% TBE PAGE gel followed by 
staining with SYBR Gold nucleic acid staining. Proper fragmented DNA products were in the 


















Figure 3-15: Correct fragmentation of Target amplicon. Correct fragmented amplicons 
should appear as a smear in the range from 20 to 200 bp (lane 3). Both over-fragmentation 







3.19.6 Labeling and Hybridization 
Fragmented DNA samples were end-labeled using DNA-labeling reagent biotin (Figure 3-11, 
step 4), which was included in the Custom array resequencing assay kit. Labeling was 
performed following the array protocol. The oligonucleotide control reagent included in the 
same kit contains a gridding control which serves as hybridization control. 
 
3.19.7 Washing, staining and data scanning 
The washing, staining and data scanning of the arrays were performed under fluidic stations 
following the manufacturer’s protocol (Figure 3-11, step 5). In order to increase the detection 
of end-labeled biotinylated probe-fragment assemblies, an additional amplification step with 
anti-streptavidin biotinylated antibody was performed which is illustrated in (Figure 3-16). On 
the left are the steps which illustrate the double streptavidin-biotinylated antibody 
amplification. Following the hybridization of target samples on the microarray, the arrays 
were scanned using the GeneChip
®






Lane 1 = Ladder 
Lane 2 = Over-fragmentation 
Lane 3 = Correct fragmentation 
Lane 4 = Under-fragmentation 
Lane 5 = Ladder 
 
1    2     3    4    5    













Figure 3-16: Streptavidin-Phycoerythrin staining with double streptavidin-biotinylated  
antibody amplification. (1) Array, (2) Target-probe hybrid, (3) Biotin binding to the target-
probe hybrid, (4) adding of Streptavidin-phycoerythrin complex which bind to biotin, (5) 
adding of Antistreptavidin biotinylated antibody, (6) second amplification of streptavidin-
phycoerythrin. 
 
3.19.8 Data acquisition and sequence data analysis 
The final data was generated and analyzed using GeneChip
® 
Resequencing Analysis software, 
version 4.0. Current base calling relies on the adaptive background genotype calling scheme 
(ABACUS) which has been developed by (Cutler et al., 2001) (Figure 3-11, step 6). This 
algorithm allows the detection of homozygous and heterozygous single nucleotide DNA 
variations such as A, C, G, T and AC, AG, AT; CG, CT, GT, respectively and “no call” if 
none of the models listed above match with the probe-target hybridization for a particular 
DNA position. The base-calling scheme calculates the likelihood of a specific model from the 
fluorescent intensities of forward probe-target and reverse probe target species, and these data 
are then used to determine the overall likelihood of a model for a given nucleotide position. 
The call rates were improved by analyzing a minimum of 15 arrays as a batch. Additionally, a 
commercially available data analysis software SeqC JSI Medical Systems was also employed.  
 
3.20 Characterization of novel DNA variants 
DNA variants were defined as novel sequence changes when they were absent in the dbSNP 
databank, in the 1000 genome project and in the literature. The degree of pathogenicity of 
each novel DNA variant were characterized using in silico biometric mutational analysis 
programs (BMAPs) which will be discussed in the next section. Furthermore, a co-
segregation of known and novel DNA variants was performed in family members where ever 




it was possible to evaluate whether the detected variant co-segregated with the disease in that 
particular family. 
 
3.20.1 in silico biometric verification of DNA variants 
A series of BMAPs, Mutation taster (MT); PMut (PMut); PolyPhen 2 (PP2), NetGene2 
(NG2), and FruitFly (FF) were introduced to evaluate the potential pathogenic effects of all 
novel mutations found with the “MFSTAAD” array. The p-scores provided by each BMAP 
were used to define the severity of a specific sequence alteration. A sequence variant was 
assigned as possibly disease-causing (PDC) if one these biometric programs listed above 
provided a p-score close to 1. To note, these scores provided here did not refer to “probability 
of error” but to “probability of prediction”, for instance a p-score close to 1 indicated a high 
certainty that the prediction was reliable. In addition to the p-score, PMut provided an r-value 
for every requested sequence alteration. The r-value was used for definite reliability of the 






4.1 Selection of different cohorts 
In this work, we have selected a large panel of subjects, the prime group consisted of subjects 
by whom MFS and/ or LDS has been suspected but were no carriers of mutations causing 
syndromic forms of TAAD, the other group were composed of probands who have been 
diagnosed for TAAD, and the remaining subset of group were subjects who died of sudden 
rupture of the thoracic aorta of unknown cause. Majority of the cases were male subjects both 
in retrospective and prospective cohorts and the age of the probands ranged from 11 years to 
58 years of age and 26 years to 81 years of age in the retrospective and prospective cohorts, 
respectively. The composition of a diverse cohorts should allow us to examine the distribution 
of disease causing mutations and type of mutation in a preselected population by which 
TAAD occur as a syndromic feature or as an isolated non-syndromic disease by using various 
molecular technology approach. 
 
4.2 Results of the custom-based MFSTAAD microarray 
Various factors in the pre-(yield of high DNA quality and quantity) and in the post PCR 
reactions such as quantitation and pooling, fragmentation and labelling have been carefully 
monitored in order to achieve a maximum quality of sequence information by high-density 
MFSTAAD resequencing microarray. 
 
4.2.1 Results of Long- Range PCR assays 
Long range PCR assay has substantially reduced the number of PCR reactions that was 
required to amplify a total of 222 coding exons plus exon-intron boundaries of eight target 
genes associated with syndromic and non-syndromic cardiovascular diseases of the thoracic 
aorta. In order to find the best long range PCR kit with minimum optimization steps required, 
we selected various long range PCR kits and compared the yield and quality of PCR 
amplicons generated from these selected PCR kits. For reliability and specificity of correct 
amplification of target DNA sequence, we have selected two control DNA samples of two 
unrelated subjects. Herein, the results of only one subject were shown, since the results were 
identical.  
4.2.1.1  KOD XL DNA polymerase Long Range PCR kit, Novagen 
KOD XL kit showed irregularity in the amplification of products <8 kb (Figure 4-1), the best 





fragments of exon 1 (lane 1), exons 4-5 (lane 3), exons 34-39 (lane 6) and exons 45-49 (lane 
7) of the FBN1 gene which did not work under any of these conditions. The same result was 
obtained for FBN1 fragments >8 kb (Figure 4-2), two of the fragments with the primer pairs 
for the exons 06-08 (lane 10) and 09-13 (lane 11) worked best at 64°C, and the primer pair for 
fragment covering exons 60-65 (lane 15) worked best at 62°C. The remaining primer pairs for 





Figure 4-1: Amplification results of fragments <8 kb of the FBN1 gene using the KOD 
XL Long Range DNA polymerase. PCR products were run on 2% agarose gel 
electrophoresis along with 1kb (+) DNA marker (M). (1) FBN1-Exon 01: 837 bp (2) FBN1-
Exon 02-03: 2.788 bp , (3) FBN1-Exon 04-05: 4.333 bp, (4) FBN1-Exon 19-23: 4.018 bp, (5) 
FBN1-Exon 24-29: 4.833 bp, (6) FBN1-Exon 34-39: 7.337 bp, (7) FBN1-Exon 45-49: 7.614 
bp, (8) FBN1-Exon 50-54: 5.297 bp and (9) FBN1-Exon 55-59: 5.860 bp. Top row A-C show 






Figure 4-2: Amplification results of fragments >8kb of the FBN1 gene using  
The KOD XL Long-range DNA polymerase. PCR products were run on a 0.8% agarose gel 
electrophoresis along with 1 kb (+) DNA marker (M). (10) FBN1-Exon 06-08: 11.950 bp (11) 
FBN1-Exon 09-13: 10.955 bp, (12) FBN1-Exon 14-18: 11.636 bp, (13) FBN1-Exon 30-33: 







A-C show the various annealing temperatures used in the corresponding PCR cycling 
condition. 
4.2.1.2  GoTaq Flexi DNA polymerase Long Range PCR kit, Promega 
For the testing of GoTaq Flexi LongRange PCR kit, a total of nine amplicons of the FBN1 
gene with a size <8 kb and six amplicons >8 kb were selected. The reaction was performed 
under two different annealing temperatures. Amplicons <8 kb were run at 58°C and 62°C 
annealing temperature and amplicons >8 kb were run at 60°C and 62°C. GoTaq Flexi failed to 
amplify fragments using primer pairs of the exon 01 (lane 1), exons 04-05 (lane 3), exons 34-
39 (lane 6) and exons 45-49 (lane 7) under annealing temperatures of 58°C and 60°C. Lane 2 
represents the amplification of exon 02-03 which worked best at 58°C. Successful 
amplification of fragments was observed for exons 19-23 using any annealing temperature, 
whereby lane 8-9 worked best at 62°C. Two bands was observed in the lane 5 using primer 
pair for the fragment 24-29, whereby the upper band was the expected PCR amplicon. This kit 










Figure 4-3: Amplification results of fragments <8 kb of the FBN1 gene using the 
GoTaq
® 
Flexi DNA polymerase. PCR products were run on 2% agarose gel electrophoresis 
along with 1 kb (+) DNA marker (M). (1) FBN1-Exon 01: 837 bp (2) FBN1-Exon 02-03: 
2.788 bp , (3) FBN1-Exon 04-05: 4.333 bp, (4) FBN1-Exon 19-23: 4.018 bp, (5) FBN1-Exon 
24-29: 4.833 bp, (6) FBN1-Exon 34-39: 7.337 bp, (7) FBN1-Exon 45-49: 7.614 bp, (8) FBN1-
Exon 50-54: 5.297 bp and (9) FBN1-Exon 55-59: 5.860 bp. Top row (A) Primer annealing 
temperature at 58°C and (B) at 62°C. 
 
4.2.1.3 Expand LongRange dNTPack Long Range PCR kit, Roche 
In the preliminary testing of Expand dNTPack LongRange PCR kit, all amplicons of the 






as instructed in the vendor’s protocol, without optimization, no successful amplification was 
achieved. For optimization purpose, we have selected three amplicons with a size of <8 kp 
and three amplicons >8 kp of the FBN1 gene were selected. Amplicons with a size of <8 kb 
were run at 58°C, 60°C, and at 62°C and amplicons >8 kb were run at 60°C, 62°C and 64°C. 
A positive target amplification result was achieved after addition of 3mM of Magnesium 
chloride (MgCl2), but only amplicons <8 kb were successfully amplified under all three 
annealing temperatures (58°C, 60°C, 62°C). No results were obtained for PCR fragments >8 






Figure 4-4: Amplification results of fragments <8 kb of the FBN1 gene using the 
Expand LongRange DNA polymerase kit. PCR products were run on 2% agarose gel 
electrophoresis along with 1 kb (+) DNA marker (M). (1) FBN1-Exon 02-03: 2.788 bp (2) 
FBN1-Exon 19-23: 4.018 bp and (3) FBN1-Exon 45-49: 7.614 bp at 58°C annealing 
temperature. Lanes 4-6 same amplicons as above under annealing temperature of 60°C and 
lanes 7-9 same amplicons as above under annealing temperature of 62°C. 
4.2.1.4 Qiagen LongRange PCR kit, Qiagen 
Under standard amplification step, the generation of amplicons of fragments <8 kb was 
successful, except for amplicon covering exons 45-49 of the FBN1 gene was not generated 
under all annealing temperatures (58°C, 60°C, 62°C) (Figure 4-5, lanes 3, 6, 9). And 
amplicons >8 kb were successful for fragments covering exons 30-33 and exons 60-65 of the 
FBN1 gene, but only under annealing temperature of 62°C. However, the complete exons of 
the FBN1 gene was successfully amplified by changing the range of amplicon size for the 
smaller amplicons to <5 kb, and by adding Q-solution, and by amplifying larger amplicons >5 
kb with three amplification cycling step with time increment of 20s in each amplification 











Figure 4-5: Primary amplification of fragments of the FBN1 gene using Qiagen 
LongRange PCR kit. PCR products were run on 2% agarose gel electrophoresis along with 1 
kb (+) DNA marker (M). Left gel picture: (1) FBN1-Exon 02-03: 2.788 bp (2) FBN1-Exon 
19-23: 4.018 bp and (3) FBN1-Exon 45-49: 7.614 bp at 58°C annealing temperature. Lanes 4-
6 same amplicons as above under annealing temperature of 60°C and lanes 7-9 same 
amplicons as above under annealing temperature of 62°C. Right gel picture: (1) FBN1-Exon 
06-08: 11.950 bp (2) FBN1-Exon 30-33: 10.108 bp and (3) FBN1-Exon 60-65: 11.424 bp at 
60°C annealing temperature. lanes 4-6 same amplicons as above under annealing temperature 









Figure 4-6: Final optimization of Qiagen LongRange DNA polymerase. Results of 
fragments of the FBN1 gene <5 kb, without Q-solution (fragments >5 kb) and larger 
fragments >5kb under a three thermal cycling condition. Pictures on top row left and bottom 
row left first 1-6 lanes represent the amplification of fragments <5 kb: FBN1 02-03, 2.788 bp; 





right represent the amplification of PCR products >5 kb: FBN1 30-33, 10.108 bp; FBN1 06-
08, 11.950 bp; FBN1 09-13, 10.955 bp. 
4.2.1.5  Final selection of a LongRange PCR kit for further analysis 
Among the serial long range PCR kits that have been tested in this study, the Qiagen 
LongRange PCR polymerase kit was the most efficient and reliable. This PCR kit had 
successfully generated all the amplicons of the FBN1 gene and the remaining amplicons of 
the seven other target genes in this study (Figure 4-7). As final step of optimization of the 
long-range PCR assay, the amplified products were verified for their specificity by 



























Figure 4-7 and Table 4-1: Coverage of 222 exons in 54 PCR products using Qiagen 
Long-range PCR kit. 
¥
Addition of 1x Q-solution in the amplification reaction. 
$
Fragments 
run at 58°C under normal cycling condition. 
§ 
Primer pair for exon 01-02 of the NOTCH1 
gene generated product at 64°C, the remaining fragments (lanes 1-16, 18-20, 22-24, 30, 33-
36, 41-42, 45-48, 53-54) were run at 62°C under three cycling conditions by which the third 
cycle was performed with 20s time increment in each additional cycle. 
 
4.2.2 Analytical sensitivity of the custom-based MFSTAAD resequencing microarray 
The overall analytical sensitivity of the microarray was 85% (154/182), while the sensitivity 
of the assay in respect to single nucleotide DNA variants was 100% (153/153) in both the 
initial experiment and in its replicate (Table 4-2). In contrast, only the largest out of the 21 
deletions tested (16 bp) was detected upon visual inspection due to a conspicuous decline in 
the hybridization strength (sensitivity rate: 4.8%). In none of the replicate experiments was 
the 25 bp duplication and the seven insertions detected (adapted from my own publication 
Kathiravel et al., 2012). Practical verification included the analysis of the impact of short 
versus long-range PCR amplicons on the overall assay sensitivity. To assay this, a further 
experiment was carried out containing exclusively long-range amplicons with a total of 51 
point mutations distributed over 3 DNA pools. Of these mutations, 48 were covered by short 
range PCR products in the initial experiments, replicate A and B. All of these mutations were 
detected correctly. 
Lanes 1-16 FBN1-02-03 (3329), 04-05 (4362), 06-08 (11950), 09-13 
(10955), 14-18 (11964), 19-23 (4083), 24-29 (4834), 30-33 
(10109), 34-35 (3163), 36-39 (3605), 40-44 (11793), 50-54 




Lanes 17-32 TGFBR2-01 (779), 02-03 (6016), 04-05 (3534), 06-07 (3573), 
ACTA2-
¥































































0/8 (0%; 0%-0.4% ) 0/8 (0%; 0%-0.4% ) 
 
Deletions  1/21 (4.8%; 0%-25.9%) 1/21 (4.8%; 0%-25.9%)  
*Seven pools of mutated PCR products were analysed with two arrays each (Replicate-A and 
–B). Given is the detection rate in percent and, in parenthesis are the interrogation rates in 
percentage with the upper and lower 95% confidence intervals calculated with Wilson score 
method (http://faculty.vassar.edu/lowry/prop1.html). 
%
3 pools with long range PCR 
amplicons containing a total of 51 point mutations. 
 
4.2.3 General performance characteristics of the MFSTAAD custom microarray of 
two different cohorts (retrospective and prospective) 
The general performance characteristics of the MFSTAAD assay were assessed using both 
retrospective cohort of 36 subjects who were mutation-negative for genes FBN1, TGFBR1 
and TFGRB2, a subset of 18 were only tested for genes FBN1 and TGFBR2; and a prospective 
cohort of 30 subjects (Table 4-3). For the total of 66 samples analyzed, an initial call-rate (i.e. 
fraction of the total of 106.322 bp which could be base-called) of 94.4% and “no-call” rate of 
5.7% was defined using the program GSEQ 4.1 data analysis software. The number of no 
calls could be resolved by using the SeqC commercially available sequence data analyzer, 
achieving an overall For the 66 samples analysed, an overall call-rate of 99.8%. The 
remaining 0.2% of ambiguous nucleotide DNA positions was found to locate within GC-rich 
sequence regions. An average of 301 DNA variants were base called using SeqC, of which 
about 90% could be corrected as wild-type upon visual inspection applying the constructed 
statistics by the software from previous runs. About 17.6% (53/301) revealed to be false 
positive DNA variants upon validation of these variants using conventional Sanger 
sequencing reaction and which were observed to be recurrent variant anomalies (for reference 





of which most of them represented to be single nucleotide polymorphisms (SNPs) and 0.4of 
which were defined as known or potentially pathogenic mutations. Only known and novel 
potentially disease causing mutations were confirmed by Sanger sequencing, because the 
remaining DNA presented mostly recurrent SNPs. 
 
Data are mean values ± SEM. *Percentage of base pairs called either A, C, G or T by the 
GSEQ program. ˚Percentage of no calls made by GSEQ. **Improved call rate achieved by 
using SeqC software. 
§
Total number of sequence variants called as homo- or heterozygous 
change by the SeqC program. 
†
Number of true single nucleotide DNA variants. 
$
Sequence 
changes which were listed as SNPs (single nucleotide polymorphisms), in the NCBI, UMD 
(Universal Mutation Database) and HGMD (Human Gene Mutation Database). 
4.2.4 Mutation yield and false positive rate 
A total of 26 mutations in 22 individuals were found with the MFSTAAD resequencing 
microarray for retrospective and prospective cohorts from Hannover and Dortmund (A 
schematic diagram on the topography of each known and novel DNA variants is found in the 
Appendix 14) (Table 4-4). The mutation yield were substantially higher (13/30) versus (9/36) 
in the prospective group than in the retrospective cohort. To note, individuals from the 
retrospective group have undergone previous genetic testing a subset of 18 were negative for 
Table 4-3: General performance characteristics of the “MFSTAAD custom-array” in 








Initial call-rate (%)* 94.4±0.2 94.0±0.3 94.8±0.4 
Initial no calls (%) ˚ 5.7±0.2 6.0±0.1 5.2±0.4 
Improved call-rate (%) ** 99.8±0.0 99.9±0.0 99.8±0.0 
called variants (n)
 §
 301±20 327±36 269±16 
retained variants (n)
 †
 26±2 29±1.4 23±2 
possibly pathogenic mutations (n)
$





a mutation in the genes FBN1 and TGFBR2 and the other half was negative for a mutation in 
an additional gene, TGFBR1. A total of eleven were among the known mutations that have 
been previously published (Table 4-5). The remaining 15 of novel possibly disease causing 
DNA variants (Table 4-6) were confirmed for their pathogenicity using in silico BMAPs and 
an amino acid alignment was performed to determine the conservation of each mutation 
between various species (Figure 4-8). Having a definite probably pathogenic effect on protein 
level (4/4 biometric programs) was obtained for the mutations FBN1 c.6821G>C), p.C2274S 
in PL22, MYH11 c.2005C>T ,p.R669C in R25; NOTCH1 c.2734C>T, p.R912W in R4 and 
ACTA2 c.598C>T, p.R198C in R14, which were predicted to affect the calcium-binding 
epidermal growth factor (cb-EGF) domain; the actin-binding domain (AB) of the myosin head 
of the myosin protein, the EGF-like domain of the notch-1 protein and in the exon 2 of the 
ACTA2 gene, respectively. A total of 9 including 5 missense mutations (DNA variants 
COL3A1 c.217G>C, p.D73H in PD20; FBN1 c.3715A>G, p.I1239V in PD19; MYH11 
c.5676G>C, p.E1892D in R6; NOTCH1 c.939C>G, p.H313Q in PD19 and TGFBR2 
c.1159G>T, p.V387L in PD18 were called as probably damaging by 2 out of the 4 biometric 
programs. The remaining 4 DNA variants were splice site changes in the genes MYH11 
(c.4116+6T>A in PD17; c.4578+3A>G in PD9; c.4791+4C>T in R4) and FBN1 
(c.442+15G>T in R9), respectively and for the potential effect on splicing was predicted 
using three different splice-site prediction programs (MT, N2G and FF). Splice changes in the 
gene MYH11 c.4116+6T>A and c.4578+3A>G showed a donor site increase by two splice 
site programs (MT and FF) and a donor site decrease was predicted by N2G. Splice variants 
(MYH11 c.4791+4C>T and FBN1 c.442+15G>T) had no potential effect on the splicing 
process. “Interestingly, a cardiac counterpart of MYH11 Arginine 669, MYH7 Arginine 663, 
has previously been found to be substituted by Serine in a patient suffering from hypertrophic 
cardiomyopathy (Richard et al., 2003)” (adapted from my own publication Kathiravel et al., 
2012). Two different mutations, one in the gene COL3A1 p.R878H and one in the gene 
SLC2A10 p.A283G were found in patient RL30 who was suspected for MFS. In terms of 
pathogenicity, the first mutation was defined as disease causing by one of the in silico 
programs, whereby the SLC2A10 gene was classified as benign. Interestingly, a previously 
found mutation p.G822A (Eder et al., 2013) in the COL3A1 gene which is located in the same 
triple helical domain and has been reported in a 28 year old female who had a classic form of 
vEDS in association with peripheral artery occlusive disease (Eder et al., 2013), thus, it would 
be interesting to know whether our patient has the same clinical phenotype. In addition, the 





predisposing effect to TAAD due to the autosomal recessive nature of the ATS; it is less 
precedent to be a disease-causing DNA variant in our case. Another patient PD19 was a 26 
year old male with an obvious appearance for classic form of MFS with thoracic aortic 
rupture, he was a carrier of two mutations in the gene FBN1 p.I1239V and p.C1860R and one 
in the gene NOTCH1 p.H313Q, from which the mutation FBN1 p.C1860R was a previously 
known DNA variant (Attanasio et al., 2008). The novel variant FBN1 p.I1239V was assigned 
as probably disease causing by 3 out of 4 in silico programs, one of the program (PP1) could 
not assign a potential effect for this particular variant, and the DNA variant NOTCH1 
(p.H313Q) was assigned as probably disease causing by 2 out the 4 programs. Due to the fact, 
that both mutations in the FBN1 gene have a potential effect on the fibrillin-1 protein it could 
be speculated that these two DNA disease causing variants alone were sufficient to cause the 
disease in PD19. In addition to the 15 novel mutations, eleven previously published single 
mutations have been detected by the array-based assay and were predicted to be disease-
causing: three in the gene ACTA2 (c.145A>G, p.M49V; c.773G>A, p.R258H; c.910G>C, 
p.G304R) and four in the gene FBN1 (c.527A>C, p.Q176P; c. 217G>C; p. R1170H; c. 
5578T>C, p.C1860R; c.6700G>A, p.V2334M) and two in the gene MYH11 (c.2005C>T, 
p.R669H; c.4676C>T, p.T1558M) (Hoffjan et al.,2011; Waldmueller et al., 2007; Hayward et 
al., 1994; Robinson et al., 2002, Attanasio et al., 2008, Tjeldhorn et al., 2006 and HGMD 
mutation database), whereby DNA variants MYH11 p.R1669H (rs111404182), T1558M 
(rs11854563) have been defined as SNPs with extremely low frequency rates of 0.2% and 
0.1% for both MYH11 variants, respectively and were in reference to in silico programs a 
“probably damaging” variants. Noteworthy, the variant T1558M has been found twice in our 
study (PD7 and R20). Another synonymous DNA variant in the TGFBR1 gene c.207C>T 
(S69S) has been listed as SNP but was predicted to have a potential effect on the splicing 
process. Additional variant in the NOTCH1 gene c.3836G>A, p.R1279H has been recently 
classified as a single nucleotide polymorphisms and McBridge et al, 2008 reported this 
variant both in control and diseased subjects. Overall, a total of 26 of potentially pathogenic 
mutations were detected in 22 unrelated patients, suggesting a yield of the assay of 33%. To 
note the mutation yield was higher in the prospective group (13 versus 9), because the 
retrospective underwent pre-screening for mutation in the genes FBN1, and TGFBR2, by 
which part of the retrospective group from Hannover were tested for an additional gene, 
TGFBR1. The results between the two retrospective group from Hannover and Dortmund 
show a slight difference in the mutation yield, 4 versus 5, accordingly which was reflective of 





target genes. In the investigated cohort, compound and digenic mutations were rare (0/66 and 
3/66, respectively). False positive mutations were detected in 9 out of 66 patients, indicating a 
false-positive rate of 13.6% of the MFSTAAD microarray. 
&
The assay has been performed in two different laboratories (Institute for Human genetics, 
Hannover and in the CorTag, Dortmund). 
%
Retrospective samples from Hannover are 
confirmed negative for mutations in the genes FBN1, TGFBR1 and TGFBR2 and from 
€Dortmund is negative for mutations in the genes FBN1 and TGFBR2. *Fraction of patients 
carrying a possibly pathogenic mutation that was confirmed by means of conventional 
sequencing, in parenthesis is the result in percent with upper and lower 95% confidence 
limits. 
§
Fraction of patients in which the software SeqC called a possibly pathogenic mutation 
that was shown to be false-positive upon conventional sequencing of the affected exon. 
 
 
Table 4-4: Mutation yield and false positive rate of the MFSTAAD resequencing assay. 
&
Laboratories Retrospective/prospective 
and total number of samples 
(n) 
*
Mutation yield n, (%) 
§




Prospective post-mortem (20) 
4/18 (22.2%; 7.3%-48.1%) 
9/20 (45%; 23.8%-68%)  
3/18 (16.7%; 4.4%-42.2%) 




Prospective pre-mortem (10) 
5/18 (27.8%; 10.7%-54%)  
4/10 (40%; 13.7%-72.3%)  
3/18 (16.7%; 4.4%-42.2%) 
1/10 (10%; 0.5%-45.9%) 
Hannover & 
Dortmund 





13/30 (43.3%; 26%-62.3%)  
 
3/30 (10%; 0.03%-27.7%) 
Hannover & 
Dortmund 
Total samples (66) 22/66 (33.3%; 22.5%-46.1%)  9/66 (13.6%; 0.07%-25%) 
Table 4-5: Previously published missense mutations 
Gene Mutation Consequence Reference 
ACTA2 c.145 A>G p.M49V Hoffjan et al. 2011 
ACTA2 c.910 G>C p.G304R Hoffjan et al. 2011 






DNA variant that has been previously described as disease causing variant in UMD-FBN1 
mutation database.
 ¥ 
DNA variants with small occurrence rate. 
Table 4-6: Affected protein domains of novel point mutation. 
Gene Nucleotide change Presumed Amino 
acid change 
Affected protein domain 
COL3A1 
c.2633G>A p.R878H TH domain 
COL3A1 c.217G>C p.D73H VWFC 
FBN1 c.3715A>G p.I1239V cb-EGF-like (20) 
FBN1 c.6821G>C p.C2274S cb-EGF-like (35) 
FBN1
$
 c.442+15G>T Splice change MT: acceptor site increased 
N2G and FF: no change 
SLC2A10 c.848C>G p.A283G TMD (8) 
FBN1 c.527 A>C p.Q176P Waldmueller et al. 2007 
FBN1 c.3509 G>A p.R1170H Hayward et al. 1994; Robinson et al. 2002 
FBN1 c.5578 T>C p.C1860R Attanasio et al. 2008 
FBN1
§
 c.6700 G>A p.V2234M 
Known as disease variant rs112084407 
Tjeldhorn et al. 2006 
MYH11
¥
 c.2005 C>T p.R669H http://www.ncbi.nlm.nih.gov/projects/SNP 
MYH11
¥
 c.4673 C>T p.T1558M http://www.ncbi.nlm.nih.gov/projects/SNP 
TGFBR1 c.207 C>T p.S69S 
Listed as SNP rs145033378 but potential 
effect on the splicing 





MYH11 c.2005C>T p.R669C AB domain, myosin head 





MT: donor site increased 





c.4578+3A>G Splice change 
MT and FF: donor site increased 
N2G: donor site decreased 
MYH11
$
 c.4791+4C>T Splice change MT: donor site increased 
N2G and FF: no change 
NOTCH1 c.939C>G p.H313Q cb-EGF like (8) 
NOTCH1 c.2734C>T p.R912W EGF-like (24) 
ACTA2 c.592C>T p.R198C Natural variant 
TGFBR2 c.1159G>T p.V387L PK domain 
The online UniProt provides information on protein sequence and functional information and 
has been used to find which domain might be affected by the corresponding DNA variant. 
TH, triple helic; VWFC, van willebrand factor c; cb-EGF, calcium-binding epidermal growth 
factor domain; AB, acting binding; TMD, trans-membrane domain; PK, protein kinase; 
$
DNA 




















FBN1 c.3715A>G (p.I1239V) 
Human  R S C T D I D E C 
Mutated R S C T D V D E C 
Put.  R S C T D I D E C 
M.m.  R S C T D I D E C 
M.m.  R S C T D I D E C 











Human  P G A R G L P G P 
Mutated P G A H G L P G P  
Put. P G A R G L P G P 
M.m. P G A R G L P G P 
M.m. P G G R G L P G P 
G.g. P G A R G L P G P  
Human  D Q E L D C P N P 
Mutated D Q E L H C P N P 
Put.  D Q E L D C P N P 
M.m.  D Q E L D C P N P 
M.m   E E P L D C P N P 
G.g.  D Q E L D C P N P 





MT: disease causing 
PM: neutral 
PP: unknown 
PP2: probably damaging 
MT: disease causing 
PM: neutral 
PP: unknown 












SLC2A10 c.848C>G (p.A283G) 
Human    V K V A A T L T A M 
Mutated   V K V A G T L T A M 
Put.     V K V A A T L T A M 
M.m.     V K V A A T L T A M 
M.m.     V K V A A T L V A T 
D.r     V K V I A T L L A M 
F.c.     V K V L A T L T A M 
 















Human  G T Y M C I C G P 
Mutated G T Y M S I C G P 
Put. G T Y M C I C G P 
M.m. G T Y M C I C G P 
M.m. G T Y M C I C G P 
G.g. G T Y M C I C G P 
Human  M T T L R N T T P 
Mutated M T T L C N T T P 
Put.   M T T L R N T T P 
M.m.   M T T L R N T T P 
M.m.   M T T L R N T T P 
G.g.   M T T L R N T N P 
D.r.   M T T L H N T Q P 
Human  E A E E E S Q R I 
Mutated E A E E D S Q R I 
Put.  E A E E E S Q R I 
M.m.  E A E E E S Q R I 
M.m.  E A E E E S Q R I 
G.g.  E A E E E S Q R I 
D.r.  E S E E E S Q R I 
MT: disease causing 
PM: pathogenic  
PP: probably damaging 
PP2: probably damaging 
 
MT: disease causing 
PM: pathogenic 
PP: probably damaging 
PP2: probably damaging 
 
MT: disease causing 
PM: neutral 
PP: unknown 
































TGFBR2 c.1159G>T (p.V387L) 
Human  S N I L V K N D L 
Mutated S N I L L K N D L 
Put.  S N I L V K N D L 
M.m.  S N I L V K N D L 
M.m.  S N I L V K N D L 
G.g.  S N I L V K N D L 
D.r.  S N I L V K N D L 
Figure 4-8: Amino acid alignment and in silico biometric analysis of novel mutations. 
H.s.  G G T C H N T H G G 
Mutated G G T C Q N T H G G 
Put   G G T C H N T H G G 
M.m.
*
  G G T C H N T H G G 
M.m   G G T C H N T H G G 
G.g.  G G T C H N N H G G 
D.r.  G G T C L N T Q G G 
Human  I D D C R P N P C 
Mutated I D D C W P N P C 
Put.  I D D C R P N P C 
M.m.
*
  I D D C R P N P C 
M.m.  I D D C R P N P C 
G.g.  I D D C Q P N P C 
D.r.  I N E C E S N P C 
Human  K I L T E R G Y S F V 
Mutated K I L T E C G Y S F V 
M.m.*  K I L T E R G Y S F V 
M.m.  K I L T E R G Y S F V 
G.g.  K I L T E R G Y S F V 
D.r.  K I L T E R G Y S F V 
F.c.  K I L T E R G Y S F V 
MT: disease causing 
PM: neutral 
PP: unknown 
PP2: probably damaging 
 
MT: disease causing 
PM: pathological 
PP: unknown 
PP2: possibly damaging 
 
MT: disease causing 
PM: pathological 
PP: unknown 
PP2: probably damaging 
 
MT: disease causing 
PM: neutral 
PP: unknown 






Gene name and nomenclature of the mutation between two panels. Left panel represent the 
conservation of each novel DNA variant across different mammals. Blue script represent the 
amino acid sequence with the mutated residue represented as bolded, red letter; Black branded 
are wild type residue for that specific amino acid change. H.s. Homo sapiens; M.m*., Mus 
mulatta; M.m., Mus musculus; P.t., Pan troglodytes; F.c., Felis catus; G.g., Gallus gallus; D.r., 
Danio rerio. Right panel represent the output for amino acid substitution; MT, Mutation 
Taster; PM, pMut; PP, PolyPhen; PP2, PolyPhen2; and FF, FruitFly. 
 
4.2.5 Novel SNPs found with the MFSTAAD resequencing assay 
On average, SNPs are found at a frequency of 1 in every 1000 bases across human genome 
(Sachidanandam et al., 2001). In this study, a total of 76 SNPs could be detected with the 
MFSTAAD microarray which were either homozygous or heterozygous SNPs (Table 4-7). A 
total of 69 SNPs have been listed in the GenBank SNP database (NCBI), whereby the 
remainder (total of 7) were novel synonymous DNA variants (Table 4-8). Majority of these 
SNPs listed herein, were recurrent among the 66 arrays analyzed. The novel SNPs were 
absent in the dbSNP database and were checked for their pathogenicity using the 
aforementioned BMAPs and were checked in the literature. 
Table 4-7: Number of reported and novel SNPs detected with the MFSTAAD       
resequencing assay 
Gene Number of known SNPs Number of novel SNPs 
FBN1 3 - 
TGFBR1 1 - 
TGFBR2 2 - 
COL3A1 13 - 





MYH11 17 3 
SLC2A10 2 1 
NOTCH1 29 3 
Total  69 7 
 
Table 4-8: Name and nucleotide position of all novel synonymous DNA variants found 
with MFSTAAD resequencing assay 
Gene Exon Nucleotide change 
MYH11 
17 c.2058+30G>A 
 32 c.4158C>T 
 34 c.4719+4C>T 
SLC2A10 3 c.1305C>T 
NOTCH1 17 c.2058+30C>T 
 32 c.4158C>T 





4.2.6 Mutation segregation analysis of known and novel DNA variants 
Mutation segregation analysis was performed in families of three decedents (PD7, PD11 and 
PD15) and in families of two living subjects (RL4 and RL6). Family segregation analysis of 
DNA variants MYH11 c.4673C>T, p.T1158M; FBN1 c.3509G>A, p.R1170H; COL3A1 
c.217G>C, p.D73H; NOTCH1 c.2734C>T, p.R912W and MYH11 c.5676G>C, p.E1892D in 
family members of PD7, PD11, PD15, RL4 and RL6, respectively can be found in Appendix 
15-19. The remaining potential pathogenic mutation could not be tested for their inheritance 
in parents and siblings due to the manner of recruitment. Co-segregation of the possibly 
disease causing mutation and the genetic disease was only observed in family 1 of PD7 for the 
mutation in the gene MYH11 c.4673C>T, p. T1558M. Conventional Sanger sequencing of the 
father of decedent 7 confirmed the same mutation. 
 
4.3 Results on the correlation between CMN and EF versus genetic predisposition 
The exact Chi-square test was used to analyse the correlation between specific 
histopathological medial changes which are characteristic for TAAD, such as CMN and EF 
versus mutation yield found in this study. In respect of the publication by Bode-Jänisch et al. 
2012 a grading score of ≥2 for CMN and EF were suggestive of a heritable disease of the 
thoracic aorta (Figure 4-9). A total of 7 subjects were carriers of a possibly disease causing 
mutation, but the majority of cases (10 subjects) had the same grade of medial changes, but 
were negative for a disease causing mutation (Table 4-9). Among the 18 decedents, one 
decedent had medial changes of grade 1 for both CMN and EF, and no subject was among 
grade 1 medial alteration with any mutation. Statistical examination showed no correlation 
between aortic alterations of CMN and EF versus genetic predisposition to a genetic disease 

























Figure 4-9: Correlation of histopathological changes (Bode-Jänisch et al., 2012) and 
genetic findings in this study. Chart represents medial alterations CMN and EF versus 
genetic mutations found in this study. CMN and EF with a medial alteration of ≥2 (Left 
column) are taken as an indication for possible genetic predisposition to a heritable disease of 
TAAD. Red column indicates a subject without a mutation and blue indicates with a mutation. 
 
Table 4-9: Correlation of cystic medial necrosis and elastin fragmentation 
versus genetic predisposition. 
PD with 
(n=18) 
Grading scores for CMN and EF 
 ≥ grade 2 grade 1 
possibly pathogenic mutation 7 1 
no mutation 10 0 
PD; prospective decedents, CMN; cystic medial necrosis, EF; elastin fragmentation. p-value 
of 0.44. 
4.4 Correlation of young age versus mutation yield 
Further interest of this study was to test whether there was a correlation between young age 
and genetic predisposition, in other words when TAAD occurred at a young age, is that 
phenomenon a good indicator for a genetic disease of TAAD. The mean age among 18 
decedents was 55.5 years (Figure 4-10). The number of mutation per decedent was higher in 





not significant using the chi-squared two tailed test (p-value of 0.11). Number of no mutation 










Figure 4-10: Correlation of genetic predisposition versus age. Chart represents age for a  
potential heritable TAD versus genetic predisposition. Mean age of ≤55.5 is taken as an 
indication of a heritable TAAD. Red column indicates subjects with no mutation and blue 
column are patients positive for a mutation in the TAAD candidate gene. 
 
Table 4-10: Correlation between age and genetic predisposition of FTAAD in a 
total of 18 decedents. 
PD with 
(n=18) 
Age of decedents 
 ≤ 55.5 > 55.5 
possibly pathogenic mutation 6 1 
no mutation 5 6 
PD; prospective decedents. P-value for one-tailed was 0.11 and for two tailed it was 0.15. 
4.5 Results of conventional Sanger sequencing analysis of the SMAD3 gene 
Conventional PCR reaction and Sanger sequencing reaction was performed in all 
retrospective and prospective samples from Hannover, since this gene have previously been 
reported to harbour mutations that cause an isolated form, the FTAAD. (Regalado et al., 
2011). This gene was not covered by the MFSTAAD resequencing microarray. A novel 
probably disease causing mutation c.1039 G>A, p.E347K was found in R14 (Figure 4-11) 





MFSTAAD microarray. For both DNA variants, all in silico biotmetric programs called these 









Figure 4-11: SMAD3 missense mutation. A novel SMAD3 mutation, c.1039G>A 
(p.E347K) detected with conventional Sanger sequencing reaction. Upper electropherogram 
the DNA variant on the forward strand, bottom electropherogram the same changes on the 
reverse strand. 
 
4.6 Characterization of exact FBN1 gene deletion breakpoints in patients I1-I3 
In our study we have identified two novel complete deletion of the FBN1 gene each in two 
unrelated patients (I1 and I2) with a classic form of MFS involving the skeletal, ocular and 
cardiovascular system and one two-exon deletion (exons 64-65) in patient I3 by whom no 
clinical information were available. Both I1 and I2 met the clinical diagnostic criteria for 
MFS. The first heterozygous FBN1 deletion in I1 encompassed the whole FBN1 gene plus 
five consecutive genes including DUT, SLC12A1, CTNX2, MYEF2 and SLC24A5 locating 
upstream of the FBN1 gene. There was no family history for MFS in patient I1. The other 
large deletion was found in I2 consisting of exons 6-65 of the FBN1 gene and deleting the 
consecutive DUT gene. This patient had multiple members from the maternal side who were 
very tall and died of unknown heart failure. Detailed medical information of these relatives 
were not available, however, he had a sister with tall stature and suffered from aortic 
aneurysm. Patient I3 had a deletion of the exons 64-65 of the FBN1 gene, by whom no 
clinical data were documented. To refine each of these deletions, we have used a 244K a-
CGH e-array. Upon a-CGH, PCR and bidirectional Sanger sequencing was used to determine 
the exact breakpoints using the information of the probe sequences that were employed in the 





the first deletion was 674.351 bp (Figure 4-15) which resided at chromosomal location: 
48.277.334-48.953.951 (676.617 bp defined by a-CGH) comprising of complete FBN1 gene 
and 3’ contiguous genes DUT, SLC12A1, CTNX2, MYEF2 and SLC24A5. The second deletion 
was 256.593 bp (257.512 bp defined by aCGH) (Figure 4-16) in length which had 
encompassed exons 6 to 65 of the FBN1 gene and the entire DUT gene. The smaller deletion 
was 9.134 bp in length (Figure 4-17) consisting of 147 bp of exon 64, intron 64, and the 
complete exon 65, the 3’UTR of the FBN1 gene and 7.484 bp of the contiguous genomic 
sequence region (Figure 4-12-14, respectively). No deletion and duplications were found in 










Figure 4-12: Determination of FBN1 gene deletions using MLPA assay. (A) Deletion of 
exons 1-65. (B) Deletion of exons 6-65. (C) Deletion of exons 64-65. Bars below 100% 
represent a deletion of the corresponding exon, and bars in the upper region of 100% 
















Figure 4-13: PCR amplification of the smaller deletion (exons 64-65 of the FBN1 gene). 
(M) 1kb (+) DNA marker. (Lane 1-3) to be ignored. (Lane 4) Amplification of deleted region 
of exons 64-65 of the FBN1 gene using primer pairs FBN1_65.1 F x R. (Lane 5) Control 









Figure 4-14: PCR amplification of large FBN1 deletions using Qiagen LongRange PCR 
kit. (Top left) Amplification of the largest deletion of complete FBN1 gene. (M) 1kb (+) 
DNA marker. (Lane 1) Patient DNA amplification using primer pairs 1 F x R, (lane 2) 
control, and (lane 3) blank, (lane 4) Patient DNA amplification using primer pairs 2 F x R, 
(lane 5) control and (lane 6) blank. Two bands were visible in lane 1, whereby the top band 
had the expected band size of about 3 kb. A gel band purification was performed for lane 1 
and lane 4 using Illustra GFX PCR DNA followed by a second PCR amplification step (top 
right); (M) marker, (lane 1) Patient DNA second amplification using primer pairs 1 F x R and 





Bottom picture represents the PCR amplification of the second largest deletion consisting of 
exons 6 to 65 of the FBN1 gene and DUT gene. (M) marker, (lane 1) DNA amplification in 
control subject using primer pairs 3 F x R, (lane 2) patient, (lane 3) blank, (lane 4) DNA 
amplification in control subject using primer pairs 4 F x R, (lane 5) patient and (lane 6) blank. 







Figure 4-15: Deletion of genes FBN1, DUT, SLC12A1, CTXN2, MYEF2 and SLC24A5 in 
I1. Deletion of 674.351 bp comprising of the complete FBN1 gene, and the genes DUT, 
SLC12A1, CTXN2, MYEF2 and SLC24A5 located 3’ of the FBN1 gene. Flags show the 
direction of the corresponding gene (either found on the 5’ or 3’ strand). The line across the 
sequence (electropherogram below) indicates the deletion breakpoint determined by Sanger 
sequencing reaction, the left sequence is the 3’ sequence of the FBN1 gene and the right 







Figure 4-16: Detection of genes FBN1 and DUT in I2. FBN1 deletion of 256.593 bp 
consisting of exons 6 to 65 and the DUT gene. The line across the sequence indicates the 





sequence of the FBN1 gene and the right sequence starting with TCTC is the 5’ sequence of 








Figure 4-17: Deletion of exons 64-65 of the FBN1 gene in I3. The smaller deletion was 
9.134 bp in length consisting of 147 bp of exon 64, intron 64, and the complete exon 65 and 
the 3’UTR of the FBN1 gene and 7.484 bp of the contiguous genomic sequence region. 
 
4.7 Indirect DNA marker linkage analysis in family 1 with promiscuous skeletal 
features 
Index patient (I6) in family 1 (Appendix 2) has been suspected for MFS with TAAD because 
several members of her family from her paternal side and her two borther had a conspicious 
Marfan habitus, and one of her uncle died of abdominal aortic rupture at the age of 65. 
Nonetheless, traditional sequencing and the novel MFSTAAD resequencing methodologies 
have revealed no mutation in eight MFS and MFS-related genes (FBN1, TGFBR1, TGFBR2, 
COL3A1, MYH11, ACTA2, SLC2A10 and NOTCH1) and MLPA was negative for deletions 
and duplications in the FBN1 and TGFBR2 genes. Furthermore, since this family was 
previously tested for linkage with DNA STR markers for MFS by Dr. Rhode as an 
independent study and she has demonstrated a linkage of the disease and markers of TGFBR1 
and TGFBR2. However, no mutation was detected using conventional Sanger sequencing 
reaction. Herein, we analysed this family using markers for FTAAD. Only two DNA markers 
for each AAT1 (D114195 and D114132) and AAT2 (D5S626 and D5S2029) have been 





markers for TAAD locus (TAAD3/BAV) and for two TAAD genes (ACTA2 and MYH11) 
mapped on chromosome 10q22-24 and 16p12.12-13.13, respectively have shown a linkage 
with the disease running in family 1 (Appendix 4 and 5). 
 
4.8 Indirect DNA marker linkage analysis in family 2 with Marfan habitus and 
aortic aneurysm 
In family 2, I9 had a Marfan habitus and aortic aneurysm. From his maternal side, he had an 
uncle with similar phenotypes, whereby his mother had only presented with a Marfan habitus. 
Furthermore, a twin sister of his grandmother died of aortic rupture of unknown cause, 
clinical data from this subject has not been available. Similarly, his cousin from the maternal 
side had aortic aneurysm, unfortunately we had no further clinical information for this subject 
either. A mutation has been found in the ACTA2 gene c.977 C>A, p.T326N which did not 
segregate with the disease running in this family. Indirect DNA marker analysis for FTAAD, 
we have been able to find a linkage between the disease and the TAAD3/BAV locus which 
maps on chromosome 15q24-16, where the disease gene remained unknown (Figure 4-18). 
The haplotype 20/23/16 for TAAD3 have been carried only by the individuals who have been 
either had a Marfan habitus or aortic aneurysm. No further linkage was found for the 
remaining two FTAAD loci and the two candidate genes (ACTA2 and MYH11) with the 
anomaly in family 2 (Appendix 6). Only two DNA markers have been informative for AAT2 










Figure 4-18: Linkage of TAAD3/BAV locus and disease running in family 2. Each 









females. Affected and unaffected individuals are represented by bold and open symbols, 
respectively. Line across denote deceased. Haplotypes for TAAD3/BAV locus are shown from 
top to bottom in the following order D11S4132, D11S924 and D11S4195. A (+) or (-) sign in 
brackets stand for mutation positive or negative of previously found DNA variant TGFBR3 
c.44C>T, p.S15F and ACTA2 c.977C>A, p.T326N. A plus sign designated mutation-positive 






5.1 Design of the novel “MFSTAAD” high density oligonucleotide based 
resequencing microarray 
Herein, we introduce the novel “MFSTAAD” high-density oligonucleotide based, a large-
scale resequencing microarray which is an “efficient and economically competitive method 
for genetic screening of heterogeneous disease” such as TAAD by enabling the simultaneous 
resequencing of a large panel of candidate genes in a single experiment (text in double quotes 
has been adapted from Kothiyal et al., 2010). This pre-screening technology will benefit in 
the identification of patients at-risk for TAAD, especially in those who fulfil the Ghent 
nosology criteria for MFS, but are non-carriers of a mutation in the FBN1 gene, which is 
known to be defected in MFS patients, and in order to differentiate classic MFS from MFS 
related syndromic and non-syndromic genetic diseases, who present with a severe form of 
TAAD. Additionally, through the parallel resequencing of several candidate genes of TAAD, 
allows a scientist to unravel the interaction between the genes/proteins in health and disease 
state, these comprehensive undertaking and elucidating the molecular pathogenisis of TAAD 
will definetly have a benefit in the clinic to manage these genetically predisposed patients at 
an early stage before a severe ruptur occurs. High-density oligonucleotide based resequencing 
microarray is a highly reliable and sensitive in the detection of heterozygous and homozygous 
single nucleotide DNA variants, which accounts for the majority of mutations found in both 
syndromic and non-syndromic thoracic aortic diseases. A series of resequencing arrays have 
been so far reported such as for hypertrophic cardiomyopathy (Waldmueller et al., 2008; 
Fokstuen et al., 2008), for dilated cardiomyopathy (Zimmermann et al., 2010) for child 
hearing loss (Kothiyal et al., 2010), for inherited retinal dystrophy (Song et al., 2011) and for 
Marfan syndrome (Ogawa et al., 2011). In the interest of my own study, until date, one 
resequencing assay by (Ogawa et al., 2011) have been reported to identify mutations in the 
FBN1 gene causing Marfan syndrome, and one next generation sequencing array which has 
been evaluated by de Leeneer et al, 2011 which covered the genes FBN1, TGFBR1 and 
TGFBR2 genes. Our MFSTAAD is the first resequencing microarary so far, that has been 
designed to identify mutations in a total of eight TAAD candidate genes (FBN1, TGFBR1, 
TGFBR2, COL3A1, ACTA2, MYH11, SLC2A10 and NOTCH1) on a single platform. 
Mutations in the gene SMAD3 has recently been described in the context of underlying 






5.1.1 Benefits of long range PCR assay for target amplification 
Target generation using long range PCR assay has a further advantage over traditional short 
range PCR reaction, in a way that this assay allows the coverage of all coding exons plus 
splice site junctions of our eight target genes in fewer as 52 PCR reactions, additionally 
reducing the handling time and cost. Several long range PCR kits have been available and 
have been employed in the generation of target amplicons for resequencing microarray, such 
as TaKaRa LA Taq polymerase (TaKaRa Bio, Madison, WT; Kothiyal et al., 2010 and Song 
et al., 2011; GeneChip CustomSeq Resequencing array protocol, Affymetrix), Go Taq Flexi 
DNA polymerase (Promega; Waldmueller et al., 2008) and LongAmp Taq DNA polymerase 
(NEB; Kathiravel et al., 2013), in addition to LongAmp Taq DNA polymerase, Hannover 
samples have been generated using the high-fidelity Qiagen LongRange Taq DNA 
polymerase for target amplification after optimizing the conditions for our target amplicons 
(Kathiravel et al, 2013, paper sent to Journal of Molecular and Cellular Probes for 
publication). 
 
5.1.2 Evaluation of the general performance characteristics of the MFSTAAD 
resequencing microarray 
For the evaluation of the general performance of our novel MFSTAAD microarray, we 
screened a total of 66 consecutive patients and achieved an overall initial call rate of 94.4% 
(66 arrays: range: 93.4%-95.7%) using the GSEQ sequence analysis software. We performed 
the base-calling under the default settings as recommended by Affymetrix for diploid sample 
data analysis. This call rate, however, varies intensively between the custom-based 
microarrays that have been reported so far, 84.8% to 98.5% (Denning et al., 2007; Kothiyal et 
al., 2010, Liu et al., 2007 ;Song et al., 2011; Fokstuen et al., 2008; Waldmueller et al., 2008 
and Zimmermann et al., 2010). It can be speculated that the discrepancy is due to the 
employment of different user-specific setting of the GSEQ data analysis software, or it can be 
based on the nucleotide composition of the different genes and the mutational heterogeneity in 
the disease analyzed. For instance, we could achieve a better call rate with larger samples 
analzed in a batch (Denning et al., and Lebet et al,.). Still, we had a no call rate of ~5.7%. 
Most of them have been found to be located in GC rich regions and in homopolymer stretches 
(mainly G-stretches). Similar observations have been reported by Denning et al; Kothiyal et 
al and Waldmueller et al. Interestingly, many studies have been performed to demonstrate the 
performance of GC rich probes under the hybridization setting in a resequencing assay which 





hybridization which lead to poorer base-calling for that regions (Cutler et al., 2001; Zhan & 
Kulp 2005; Waldmueller et al., 2008). This would be a limitation of the assay, if a disease-
causing mutation lies within G-stretches. One way to overcome this limitation and improve 
the overall call rate, is to adjust the probe length of G-rich probes, and to intergrate a known 
variable base at either end of the probe (Southern et al., 1999;Waldmueller et al., 2002 and 
2008), another way would be to generate a triplicate set of probes for each reference base 
(“triplicate design”- Zimmermann et al., 2011) by which each of these probe sets contained a 
different position of interrogation such as positions 9,13 and 17 within the 25-mer probe. This 
strategy has shown to have dramatically improved the call rate. Our current study, utilizes a 
duplicate design without the probe modification. Furthermore, we have used a commercially 
availabe Sequence Pilot module SeqC software which recalculates the base-calling of “no 
calls” assigned by GSEQ. With this software we could substantially reduce the number of “no 
calls” and achieved a final call rate of 99.8%. The remaining 0.2% (~1.3kb of target 
sequence) of no base-calling was visually inspected and in the case of relevant sequence 
region it was resequenced using conventional Sanger sequencing reaction. These results were 
comparable with other algorithm software and user-defined criteria as post GSEQ data 
analysis (Kothiyal et al, 2010 and Song et al., 2011, respectively). In the study of Song et al, 
they filtered out the variants that cause “SNP nearby effect”, which means that a true variant 
is most likely to impulse false variation calls at positions of about 10 bases on either side of 
the true variant. These abnormality calls has been also observed for our array samples (Figure 
5-1), in most cases if it has been conspicuous for a true variant this change has been 
confirmed with conventional Sanger sequencing reaction. In most cases these were false 
positive and were recurrent, thus they have been ignored in further analysis. 
 
5.1.3 Analytical Sensitivity of the MFSTAAD microarray 
The MFSTAAD microarray has shown an analytical sensitivity of 100% (153/153) for both 
known and novel single nucleotide DNA variants using a duplicate tiling system. Same 
sensitivity has been achieved by Zimmermann et al., using a triplicate probe array design with 
interrogation sites on positions 9, 13 and 17. However, the assay has a reduced sensitivity for 
insertions and deletions (4.8%; 1/21) which constitutes of ~19.5% of all known TAAD 
mutations, with the FBN1 gene contributing to 17.4% (22.3% of all known FBN1 mutations; 
Human Gene Mutation Database. Upon interrogation of 21 known deletions (size range: 1 to 
16 bp), we could detect the largest deletion (Figure 5-2) due to a dramatic decline in the 





samples. Similar observation has been described by Fokstuen et al.,. Noteworthy is, that the 
SeqC software has failed to call this variant, thus it would have remained unseen, if it was an 
unknown variant. Whereby, Kothiyal et al., have reported the detection of the largest deletion 
through a series of “no calls” and a heterozygous call within the expected deleted region. 
Similarly, “the DCM assay by Zimmermann et al. outperformed the MFSTAAD assay and 
other similar assays in respect to the detection of insertions and deletions (42% vs. 5% in our 
case) by performing a “best case/worst case” scenario. Thus, the detection rate of insertions 
and deletions by the MFSTAAD assay may be improved by the modification of interrogation 
site in the duplicate probe design (interrogation of DNA variants at different sites in the 25-
probe). At present, however, the inability to detect small heterozygous insertions and 
deletions presents a significant limitation of the “MFSTAAD” assay. Nevertheless, in 
comparison to traditional methods such as conventional Sanger sequencing, the “MFSTAAD” 
array allows the parallel sequencing of eight TAAD candidate genes in a single experiment, 
which is highly preferred in the routine clinical setting due to the maxmum gain in time, labor 
and cost-efficiency of the assay. To date, the largest platform allows interrogation of 300 kb 
of target sequence, which has been reported by Booij et al., for retinal disease. Certainly, new 
large-scale platforms such as “next generation sequencing microarray platforms” are taking 
their placement in the clinical diagnostic and will soon replace all the other large scale 
technologies, to date their main limitation lie in the data handling and are still too costly for 
medium sized or for disease-specific applications. Thus, we are highly convinced, that the 
“MFSTAAD” array, is a good pre-screening tool for the detection of single nucleotide 
variants due its ability to analyze a large panel of genes in a single experiment with a 
reasonable turn-around time and cost-efficiency. The resequencing assays for child hearing 
loss and dilated cardiomyopathy have shown to reduce the cost by ~50% when compared with 
conventional Sanger sequencing reaction (Kothiyal et al., 2010 and Zimmermann et al., 
2011). Further refinements in base-calling algorithms for indels (e.g. algorithm that detects 
regional drop in signal intensity indicative of possible deletions) and for DNA variants in G- 
rich probes will make this technology even more favourable both in research and clinical 
environments. In the interim, the “MFSTAAD” array is used for the detection of single 













Figure 5-1: A “SNP nearby effect”. Single nucleotide variant in the exon 11 of the FBN1 
gene (c.1415G>A; rs4775765 decreases the signal intensity for the probes of contiguous 









Figure 5-2: SeqC electropherogram result of a 16 bp deletion in the FBN1 gene. SeqC 
defines a position based on the signal intensity of perfect match probes for the corresponding 
position based on the existing chip files with same chemistry found in the database. (A) In the 
first diagram (control), straight line running horizontally (see arrow above) represents strong 
hybridization strength from a normal patient. In addition, the sequence electropherogram of 
this subject remains uniform throughout the region of interest. (B) The hybridization strength 
displays a drop (see bottom diagram) that corresponds to a weak hybridization process and an 
irregular flow of the sequence electropherogram is also observed in this patient (see diagram 





5.1.4 Evaluation of mutation yield of the MFSTAAD microarray 
Using the “MFSTAAD” resequencing array, we could detect a total of 22 mutations in 66 
unrelated patients with classic MFS or diagnosed for TAAD, among these, a total of 9/22 
were known and a total of 13/22 were novel DNA variants, corresponding to an overall 
mutation yield of ~33%. Similar mutations yield was observed by Fokstuen et al., for their 
HCM resequencing microarray. Noteworthy, when considering the mutation yield in our 
prospective cohort who consisted of blinded samples who were not previously tested for 
mutations in any of these eight TAAD genes, the mutation yield has been 45%, higher than 
the detection rate observed for the retrospective group (45% versus 22.2%). Thus, the chance 
to detect a possibly disease causing mutation in clinical setting is ~45%. The absence of 
mutations in the remaining 44 samples may be due to the inability of the “MFSTAAD” array 
to detect indels as discussed above, or presence of mutations in the regulatory elements which 
are not covered in the design of the resequencing assay, mutations in other previously found 
TAAD such as SMAD3 (Regalado et al., 2011) and MYLK (Wang et al., 2010) which were 
unknown during the “MFSTAAD” array design, or the presence of mutations in still 
unidentified TAAD genes, and due to the fact of sample bias. Since 36/66 samples were 
previously tested for MFS and LDS-specific disease genes (FBN1, TGFBR1 and TGFBR2, 
respectively). The assay may have a limited application in the clinical diagnosis of TAAD 
patients, as indels account for ~17.4% and ~19.5% of all TAAD mutations, however, 
modification in the probe design and a suitable algorithm for the detection of indels using 
GSEQ data analysis software are attempted which will hopefully improve the mutation yield 
of the MFSTAAD assay. 
 
5.2 Reduced penetrance and variable expression of MYH11 p.T1558M 
Following the evaluation of pathogenicity of novel DNA variants using in silico BMAPs, we 
have further evaluated the pathogenic effect of novel and known DNA variants MYH11 
c.4673 C>T, p.T1558M; FBN1 c.3509 G>A, p.R1170H; COL3A1 c.217 G>C, p.D73H; 
NOTCH1 c.2734 C>T, p.R912W and MYH11 c.5676 G>C, p.E1892D in close relatives of 
PD7, PD11, PD15, RL4 and RL6, respectively. Results of mutation segregation analysis are 
depicted in the Appendix (Appendix 15-19). A co-segregation of a mutation and the disease 
has been observed in PD7 for the mutation MYH11 (p.T1558M). This variant has been listed 
in the NCBI dbSNP database with a reduced occurrence rate of 0.1. Medico-legal reports of 
PD7 has been available, this individual has a tall stature and died of TAAD. Upon genetic 





examine the segregation of this DNA variant within the family. Medical records of the father 
revealed the presence of aortic aneurysm, confirming that this variant is possibly the disease-
causing variant, however, showing reduced penetrance and variable expressivity in the father. 
Other four variants did not co-segregate in the family; however, they have been made aware 
of potential risk of FTAAD (Boileau et al., 2005; Milewicz et al., 1998). 
 
5.3 Evaluation of correlation of histopathological changes versus genetic 
predispotion to TAAD 
Specific histopathological features such as CMN and EF have been suggested by the group of 
(Bode-Jaenisch et al., 2012) as indicators for MFS and other related thoracic aortic diseases. 
They have shown quantitative difference in the grade of CMN and EF between the group of 
decedents with dissecting aneurysms and group of decedents without dissecting aneurysms, 
with statistically significant p-value of <0.001. These results are in accordance with 
Schlatmann & Becker, 1977, particularly for EF upon comparing the normal aging aorta and 
abnormal aortas with TAAD. Whereby, Hasleton & Leonard, 1979 found local EF in the 
majority of patients with a dissecting aorta, but also in the control aortas. In addition, they 
could not determine a difference in the grade of CMN between cases with TAAD and control 
groups. Similar results have been found in our study with substantially higher grades for 
CMN and EF in the group without a mutation, and confirm that there is no correlation 
between CMN and EF and genetic predisposition to FTAAD (p-value of 0.44). As an 
evidence for a possible misinterpretation of histopathological results, we show in Figure 5-3 
variable grading scores (1, 2 and 3) for CMN and EF from three different decedents (D15, 7 
and 19) carrying one or more potentially pathogenic mutations. If the decisions for a genetic 
background of TAAD will be made solely upon histopathological grounds then D15 with 
grade 1 alteration for CMN and EF with a mutation in the gene COL3A1 (c.217C>G, 
p.D73H) would have been missed out. In addition, D19 suspected of MFS with TAAD with 
two mutations in the FBN1 gene and one mutation in the gene NOTCH1 show only grade 2 
alterations for CMN and EF, whereby grade 3 alterations for CMN and EF have been 
observed in D7 by which a rare DNA variant in the gene MYH11 (c.4673C>T, p.T1558M) 
has been found. Therefore, we suggest that high grades for CMN and EF are not necessarily 
specific features of a heritable disease of the aorta and should be used in caution when these 
information are used for the decision whether a relative of the decedent is affected or not. 
And rather confirm that these changes in the aortic wall occurs with age (Schlatmann & 





defects or other factors such as hypertension, hypercholestemia and smoking (Ince & 
Nienbar, 2007). Interestingly, Ince & Nienbar have also reported a functional role of matrix 
metalloproteinases (MMPs), which is a group of more than 20 zinc-dependent proteolytic 
enzymes in the ECM metabolic events, aortic wall remodelling, and have speculated to have a 
potential role in the development of aortic aneurysms and dissections. More specifically, due 
to a localized increase in MMP-8 and MMP-9 enzymes. A polymorphism in the MMP-9 (-
8202A>G) have been reported to have a potential role in the TAA development, but the 
functional role of this variant remains to be examined (Chen et al., ). For instance, murine 
models without MMP-9 have shown that complete loss of MMP-9 gene (Mmp-9) have a 
delayed TAA development. Furthermore, Wilson et al. has reported a case with a localized 
increase in expression levels of MMP 8 and MMP-9 at the site of abdominal aortic rupture 
leading to exhilarate aortic expansion and rupture in this individual. Similar observations 
have been made in individuals with TAAD (Ikonomidis et al., 2006). This suggests, that 
MMP9 may have a potential role in the TAAD development and it would be of interest to 
study this gene in our cohort, by whom TAAD has occurred unexpectedly. This will not only 
widen our understanding on the pathogenesis of TAAD, and possibly enable a targeted 
mecical treatment to decrease the levels of MMP-9 in patients with TAAs which may 































Figure 5-3:  Comparison of specific medial alteration in respect of Cystic medial 
necrosis (CMN) and Elastin fragmentation (EF). Medial changes: grade 1, mild; grade 2, 
moderate and grade 3, severe. Upper row left (A) represents grade 1 alteration (H&E, 200:1) 
aortic specimen of a decedent carrying a missense mutation in the COL3A1 gene c.217G>C, 
p.D73H. Upper row right (B) grade 3 alterations (H&E, 100:1), carrier of a missense mutation 
in the MYH11 gene c.4673C>T, p.T1558M. Bottom row left and right (C and D) grade 2 
alterations for EF (EVG, 200:1) and grade 2 alterations for CMN (AB, 200:1) in a decedent 
carrying a digenic mutation in the FBN1 gene (c.3715A>G, p.I1239V; c.5578T>C, 
p.C1860R) and one mutation in the NOTCH1 gene (c.939C>G, p.H313Q). 
 
5.4 Evaluation of the correlation of age versus genetic predisposition 
Nonetheless, we highly believe that TAAD occurring at young age can be considered for a 
syndromic or non-syndromic genetic disease of the thoracic aorta, in the absence of other risk 
factors such as hypertension, hypercholesterolemia and habit of smoking. Klintschar et al,. 
has reported three cases on sudden, unexpected TAAD as a result of a genetic disease and 
have raised the importance of a genetic screening in close-relatives of young decedent died of 
unexplained TAAD, due to the fact that about 20% of TAAD can present in several close-
relatives. In this work we have tested the correlation between genetic predispositions versus 








> 55.5 years). Upon testing this phenomenon, we have observed that the mutation rate, hence 
genetic predisposition to TAAD, was higher among the young adults compared to old 
generation (6 versus 1). However, the difference was not significant (p-value of 0.11). This 
may be explained by our large number of decedents >55.5 years of age, by which aortic 
dissections possibly occurred as an event of normal degeneration of the aortic wall (Larson & 
Edwards, 1984) or our sample size has been far to small for a correlation study, and our study 
include sample bias. In a case report by Klintschar et al., a young adult that died of sudden 
aortic rupture was described to have remarkable skeletal phenotypes of MFS. Molecular 
testing of the FBN1 gene, revealed a disease-causing mutation. Similarly, we describe herein 
a young adult who died of TAAD who is a carrier of a digenic mutation in the FBN1 gene 
(c.3715A>G, p.I1239V; c.5578T>C, p.C1860R) and one mutation in the gene NOTCH1 
c.939C>G (p.H313Q). In this individual a classic MFS was suspected due to his skeletal 
features conspicuous for a connective tissue disorder, however, subjects with FTAAD do not 
present with any of the syndromic features, which makes the identification of these 
individuals at-risk very difficult in a clinical setting, and are generally overlooked until a 
tremendous complication of the aorta occurs. Thus, only way to prevent this type of 
complications from reoccurring, is firstly through careful documentation in the medico-legal 
autopsies, and to contact directly or indirectly close relatives in order to inform potential risk 
of FTAAD and to invite them for a genetic counseling. This approach will allow commencing 
a preventative management and reducing the mortality and morbidity rate associated with 
genetic forms of TAAD (Klintschar et al., 2009; Hirani et al., 2008; Ripperger et al., 2009). 
 
5.5 Classic MFS caused by true haploinsufficiency of the FBN1 gene 
To date, over 2000 mutations have been described for the FBN1 gene in the UMD-FBN1 and 
only a few of these are recurrent DNA variants. Missense mutations are the most prevalent 
DNA variants reported for the FBN1 gene. Other mutations include frame-shift, splice-site 
and nonsense mutations (Faivre et al., 2007) and each of these show a variable expressivity in 
the clinical phenotype among MFS patients (Boileau et al., 2005). MFS is generally 
characterized into three forms including neonatal, severe and classic MFS. Specific hot spot 
region in the FBN1 gene have only been described for the neonatal form of MFS (FBN1 
exons 28-32), whereby the mutations causing severe to classic form of MFS are distributed 
over the entire FBN1 gene. To date, only a few large deletions encompassing single and 
multiple exons have been reported and have been shown to be associated with a severe form 





2008); an in-frame deletion encompassing exons 42-43 in a case with classic MFS (Liu et al., 
2001) and most recently, Hilhorst-Hofstee et al., 2011 reported the first series of 10 patients 
with a whole FBN1 gene deletions causing a range of mild to severe form of MFS, caused 
purely by the true haploinsufficiency of the FBN1 protein. Five of their unrelated patients had 
a deletion beyond the FBN1 gene, spanning 1-9.4 MB, deleting further 1-46 consecutive 
genes. Similar deletion spanning have been described by another group (Furtado et al., 2011) 
and has been observed in our patient 1 and 2 who have a classic form of MFS, except that 
breakpoints, size and the position has differed among these three groups. Noteworthy is that 
patient 2 is a carrier of a heterozygous deletion which consits of exons 6-65 of the FBN1 gene 
and the consecutive DUT gene. Regardless, of the deletion of additional five consecutive 
genes (SLC24A5, MYEF2, CTXN2, SLC2A1 and DUT), these two patients have not exhibited 
any additional clinical features than seen in a classic form of MFS. Similar observations have 
been reported by Hilhorst-Hofstee et al,. in two patients who have presented with even larger 
deletions of 9 further genes including the FBN1 gene. These findings not only support the 
hypothesis that true haploinsufficiency can lead to classical phenotype of MFS (Matyas et al., 
2007), but additionally that the loss of the five further genes upstream of the FBN1 does not 
have an additional impact on the clinical appearance of MFS patients. Nevertheless, Hilhorst-
Hofstee et al,. described two further patients with an extended phenotype of mental 
retardation and dysmorphic abnormalities in addition to classic MFS, by which one patient 
has shown even more severe neurological features exhibiting lack of skin and hair 
pigmenation (Hilhorst-Hofstee et al., 2011), however. These severe phenotype have been 
attributed to the loss of genes Myosin 5A (MYO5A, MIM-160777) and RAS-associated 
protein (RAB27A, MIM-6033868) which are both located downstream of the FBN1 gene 
leading to haploinsufficiency of additional two genes including FBN1, whereby deletions 
described in our study and by Furtado, et al., have been found upstream of the FBN1 gene. 
Several reports exists who described deletion of downstream genes, with similar psychomotor 
features (Faivre et al., 2007; Ades et al., 2006; Hutchinson et al., 2003), whereby Hutchinson, 
et al. described a deletion extending further into centromeric portion of the chr. 15q. The sizes 
and breakpoints of these deletions remains unknown. Furthermore, within the group of whole 
FBN1 gene deletion, the clinical phenotype can vary substantially from mild to severe 
classical form of MFS. This phenomenon has also been seen between patient 1 and 2, the first 
deletion encompassed the whole FBN1 gene and five further genes, this patient exhibited a 
classic form of MFS with involvement of the skeletal, ocular and cardiovascular system, 





deletion started in exon 6, but had a severe form of MFS, and received a heart transplantation 
at young age. Hutchinson et al., has reported that levels of fibrillin-protein and mRNA 
transcripts have been significantly higher than expected for a single FBN1 allele in a patient 
with whole FBN1 gene deletion and suggested that the variable clinical phenomenon seen in 
MFS patients could be explained by the variable expression of the wild type fibrillin-1 protein 
upon comparing this results with three members in a family with a PTC mutation showing 
variable expression of the normal fibrillin-1 allele. Thus, it would be interesting to know 
whether the hypothesis of “variable phenotpyic appearance in MFS is due to variable 
expression of the wild-type fibrillin-1 protein”, can explain the different clinical phenotpye 
between patients 1 and 2 in this study. But in respect of these previous work on fibrillin-1 
expression, it shows that a complete loss of fibrillin-1 allele is rather compensated by normal 
fibrillin-1 allele than when high levels of mutant fibrillin-1 are present which may explain the 
severe form of MFS in patient 2. Therefore, a mRNA analysis for this patient would be a 
benefit of to understand the fibrillin-1 function in MFS patient with a mutant fibrillin-1 
compared to those with a loss of one fibrillin-1 allele. Furthermore, we have found a two-exon 
mutation encompassing exons 64-65 of the FBN1 gene in a patient by whom no clinical signs 
have been documented. We believe that this is the first deletion so far described to include the 
complete deletion of last exons of the fibrillin-1 gene, which is important for the termination 
of the protein synthesis. Fibroblast analysis has been performed by Dr. Keyser, institute of 
Human Genetics and she has found a reduction in the fibrillin-1 protein levels. In our cohorts 
of 20 decedents, who died of sudden, unexpected TAA has shown no larger deletions and 
duplication in the FBN1 and TGFBR2 gene using the MLPA-P065 and P066 kits. This could 
be due to several factors such as, these patients DNA have been obtained from tissue samples, 
in the MLPA analysis we have observed false positive expression levels across both FBN1 
and TGFBR2 genes, upon repeating and comparing with reference samples, these reduction or 
increase in copy numbers have not been recurrent and indicative for a true copy number 
changes, indicating of possibel carry overs during the extraction of genomic DNA using 
phenol-choloform extracton method. This may be improved by using automated DNA 
purification kit such as the QIAamp DNA Mini QIAcube kit which has been modified for the 
use of DNA extraction from human tissue. Another reason may be that these patients may 
harbour a large DNA variant in exons 1, 11-12, 21, 23, 28, 33, 38, 40, 49 52, and 60 of the 
FBN1 gene or in exon 2 of the TGFBR2 gene, which has not been covered by the recent 
MLPA kit. Or these patients may harbour deletions or duplications in other genes that have 





with TAAD such as COL3A1, ACTA2, MYH11, SLC2A10 and NOTCH1 gene which are not 
covered by todays MLPA kits. Mosaicism and copy number rearrangements are also not 
covered by this assay, which seems to be one of the limitation of the assay: Nevertheless, kits 
containing probes for further TAAD linked genes may be a benefit to locate deletions and 
duplications in these genes. Further MLPA kits are avaliable for complete exons of the genes 
TGFBR1 and TGFBR2 (P-148, MRC-Holland, Netherlands), with the exception of exon 2 in 
the TGFBR2. Nonetheless, major pathogenic mutations for TGFBR1 and TGFBR2 have been 
predominantly missense or splice–site mutations (Faivre et al., 2007). So far only one de novo 
14.6 MB duplications have been localized in the TGFBR1 gene on chromosome 9p22.32q31.2 
in a 17 year old girl with dysmorphic features indicative for LDS, however, so far no 
deletions have been described for both TGFBR1 and TGFBR 2 genes (Furtado et al., 2011), 
which coincides with our findings that large DNA changes are very rare in the two latter 
genes. 
 
5.6 Evaluation of indirect DNA marker analysis in two unrelated German families 
Indirect genetic analysis with polymorphic short tandem repeat DNA markers for TAAD are 
useful application in families who are clinically obvious for MFS or MFS-related heritable 
diseases, but do not completely fulfil the Ghent nosology criteria or the index patient is 
negative for mutation in the FBN1 gene using conventional Sanger sequencing or other 
sequencing methodologies. This is a good alternative approach of traditional sequencing 
methods since it reduces the impact of sequencing complete exons of all TAAD candidate 
genes, which can be too expensive and time consuming. Herein, we have found no linkage of 
TAAD markers and the disease running in family 1 (patient I6), where several members in the 
family have shown typical skeletal abnormality and manifestation of the cardiovascular 
system. Only five family members have been available for the analysis, which is a small 
group to get a good and reliable result. In family 2 (patient I9), a linkage has been found for 
the marker of TAAD3/BAV and the disease, by which the marker haplotype (20/23/16) 
segregated with the disease in family 2 (patient I9). Till today, the disease gene remains 
unknown for this locus (Elliso et al., 2007). Goh et al., has reported the first case on genetic 
linkage of TAAD3/BAV in several family members who have exhibited BAV with ascending 
aneurysm. Similar phenotypes have been found in multiple family members in our family. 
Thus, patients will benefit from the identification of the disease gene for this loci and the 
other two TAAD loci (AAT1 and AAT2), this could only be done by studying a panel of large 





criteria for MFS but show features which are typical of a MFS patient or by simply 
sequencing this marker region where we found to segregate with the disease in family 2 
(patient I9). Once the disease gene is identified, either conventional Sanger sequencing 
reaction or the novel MFSTAAD resequencing assay can be performed in order to look for a 
disease-causing mutation. Furthermore, abnormal MMPs and their inhibitors have been 
described in the context of aortic aneurysms (Knox et al., 1997). A total of 20 
metalloproteinases exists and are shown to play an important role in the ECM metabolism and 
aortic wall remodelling (Galis & Khatri). A gene cluster encoding several MMPs, especially 
MMP1, MMP3, MMP8 and MMP10 maps to the same chromosome 11q like the AAT1 locus. 
Interestingly, gene encoding MMP-8 has been reported to be upregulated in patients with 
abdominal aortic rupture (Wilson et al., 2006), similar clinical feature have been found in 
family 2. Furthermore, an additional gene encoding for MMP9 has shown to be involved in 
the formation of aortic aneurysms and dissections in the thoracic aorta, which is mostly 
described in FTAAD, and in syndromic form of TAAD such as MFS. Showing further 
evidence for a potential role of MMPs in the pathogenesis of the heterogenous TAAD disease. 
Thus, it would be worthwile to test markers spanning this MMP gene cluster on chromosome 
11q2, and additional markers covering the gene MMP9 mapping on chromosome 20q13.12 in 








In conclusion, this study shows that MFSTAAD microarray platform is an appropriate, rapid 
and cost-effective mutation analysis tools by which it allows parallel mutation analysis of all 
target genes in a single experiment. The microarray facility allows a custom array design in 
which all sequence positions of interest can be interrogated by specific short oligonucleotide 
probe sets. Through the parallel sequencing of candidate genes that encode for proteins which 
may play a role in the pathogenesis of TAAD allows scientists to gain a better understanding 
on the interaction among the proteins that maintain normal aortic function and under a disease 
status. Such genetic testing with MFSTAAD microarray is definitely a golden standard tool, 
by which it may help to identify at-risk relatives of patients with FTAAD; still a follow-up 
sequencing test is required to rule out the presence of large gene deletions and insertions, such 









Gender F M 
Age 23 22 
Skeletal pectus carniatum, reduced 
US/LS, wrist/thumb signs, 
protrusion acetabuli, PES planus 
general joint laxity, tall, scoliosis  
Cardiac mitral valve prolapsed without 
mitral valve insufficiency, 
dilatation of the pulmonary 
artery 
mitral valve prolapsed with mitral 
valve insufficiency, severe aortic 
aneurysm, achieved a heart 
transplantation,  
Ophthalmologic ectopia lentis lens luxation 
Craniofacial Palate anomaly, 
microretrognathie 
arched mouth causing problems 
with teeth 
Family history for 
MFS/TAAD 
Unknown Yes 
Appendix 1: Clinical signs of two individuals with classical MFS.
 §
 This patient has a 
sister who is tall and has an enlarged aorta, several close relatives from his maternal side are 
tall people and several people died of unknown heart failure. Clinical data of the relatives 












Appendix 2: Familiy pedigree 1 with Marfan syndrome with/ without aortic aneurysms 
carrying two non-synonymour DNA variants in the TGFBR3 gene (c.44C>T, p.S15F and 





Symbols with a line across represent a deceased subject. Round bolded symbols represent 
individuals affected by MFS. (I6) is the index patient in this family. From the paternal side of 
the index patient, one of her uncle (I2) was a tall (190 cm) and thin person who died of 
abdominal aortic rupture at the age of 65. Her father (I3) was also a tall person (190 cm) and 
died of lung disease at the age of 80. The index patient has a normal height (168 cm) 
compared to her father and two brothers (7 and 8, both 190cm tall). Both of her brothers have 
pectus excavatum and her daughter (I9) is highly suspected for MFS. No mutations have been 
found in the genes FBN1, TGFBR1 and TGFBR2, but two variants were detected by Singh et 
al., 2012, which did not co-segregate with the disease. A (+) or (-) sign in brackets stand for 
mutation positive or negative of previously found DNA variant TGFBR3 c.44C>T, p.S15F 
and c.55A>G, p.T19A. A plus sign designate mutation-positive and minus sign for mutation-
negative for the respective DNA alteration.   
 
 
Appendix 3: Family pedigree 2 with Marfan habitus and aortic aneurysms/rupture 
with one non-synonymous DNA variant c.55A>G (p.T19A) in the TGFBR3 gene and one 
disease-causing mutation in the ACTA2 gene c.977C>A (p.T326N). Round symbols 
indicate female and square symbols stand for male. Line across indicate deceased subjects. 
Filled symbols indicate affected individuals. Index patient (I9) has a Marfan habitus with 
aortic rupture. His sister (10) is a normal subject. From the maternal side of the index patient, 





(2) of the mother of the index patient died of aortic aneurysm at the age of 33 years of 
unknown cause. Father of the index patient (3) died of lymphoma. A (+) or (-) sign in 
brackets stand for mutation positive or negative of previously found DNA variant in the 
TGFBR3 gene c.44C>T, p.S15F and ACTA2 gene c.977C>A, p.T326N. A plus sign designate 
Mutation positive and minus sign for mutation-negative for the respective DNA alteration.   
 
 







Appendix 4: Indirect marker analysis for FTAAD in family 1 using markers for TAAD 
loci. The numbering correlates with the family pedigree in appendix 2. Squares represent male 
member and circles stand for females. Affected and unaffected individuals are represented by 
black bold and open symbols, respectively. Line across denote deceased. A (+) or (-) sign in 
brackets stand for mutation positive or negative of previously found DNA variants in the 
TGFBR3 gene, c.44C>T, p.S15F and c.55A>G, p.T19A. A plus sign designate mutation-
positive and minus sign for mutation-negative for the respective DNA alteration. Top left are 
haplotypes for TAAD1 locus (top to bottom D5S626 and D5S2029). Haplotypes for AAT1 
locus (top to bottom D11S4132 and D11S4195) are shown on the top, right panel. Bottom 
right are the haplotypes for TAAD3/BAV locus (top to bottom D15S158, D15S205 and 
















Appendix 5: Indirect marker analysis for FTAAD in family 1 using markers for TAAD 
candidate genes ACTA2 and MYH11. The generation and subject number correlate with the 
original pedigree numbering in the appendix 2. Squares represent male member and circles 
stand for females. Affected and unaffected individuals are represented by bold and open 
symbols, respectively. Line across denote deceased. A (+) or (-) sign in brackets stand for 
mutation positive or negative of previously found DNA variant TGFBR3 c.44C>T, p.S15F 
and c.55A>G, p.T19A. Left panel are haplotypes for the MYH11 candidate gene (MYH11 
locus) from top to bottom D16S3046, D16S3103 and D16S3102, respectively. Right panel 
are haplotypes for ACTA2 candidate gene of TAAD (ACTA2 locus; right panel) from top to 























Appendix 6: Indirect marker analysis for FTAAD in family 2 using markers for 
candidate genes ACTA2 and MYH11. Subject numbers are indicated with numbers. Squares 
represent male member and circles stand for females. Affected and unaffected individuals are 
represented by bold and open symbols, respectively. Line across denote deceased. A (+) or (-) 
sign in brackets stand for mutation positive or negative of previously found DNA variant 
TGFBR3 gene c.44C>T, p.S15F and ACTA2 gene c.977C>A, p.T326N. A plus sign designate 
mutation-positive and minus sign for mutation-negative for the respective DNA alteration.  
Left panel are haplotypes of AAT2 locus (top to bottom D5S641 and D5S626) shown below 
each respective individual. Haplotypes for AAT1 locus (top to bottom D11S4132, D11S924 
and D11S4195) are shown on the top, right panel. Bottom left panel are haplotypes for the 
MYH11 candidate gene (MYH11 locus) from top to bottom D16S3046, D16S3103 and 
D16S3102, respectively. Bottom right panel, are the haplotypes for ACTA2 candidate gene of 










Appendix 8: Primer pair for fibrillin-1 (FBN1) Gene 
Primer description Primer sequence 
(5’      3’) 



























FBN1_E14F CATGCACATGCCAAAACTCAAGAACT 11,964 
Appendix 7: Primer sequence flanking genetic markers. 









D5S626 ACCTGCACATGTACTCTCTGA CATGGAAGGAGCCTGTATAA 100 13 




D11S4132 GTGCAAGTTTTGGCTTCGTC ACTCCAGCCTGGGTGAAA 206 23 
D11S924 TAGAGTGAGACTCTGTCTCAAACA GAGGGATGGACTAGCCTAAA 119 17 
D11S4195 GTGGCCCAGGCTGTTC GCTGCTAAATGTCACACTGAGA 275 17 
D15S158 CAGGAGACCTCCAAACACA TTTCAGCCAAGAAGCACG 87 20 
D15S205 CTTAATGGTTTGGCAGGATA AGCTTAAAANCAAAATCTCCC 160 31 
D15S115 TACACAAATGGTACACTTTCCA TGGCTGGGTCTCTACATTTA 115 18 
D16S3046 CCCAGAATAAACTGCGTG TTCATGGACCCCCTATTG 233 22 
D16S3103 GCTTTGAGTCTCCACATCTATGA GGCCAGCAGGTCTTCCTA 102 14 
D16S3102 CATGGGGACTCTGGCTAAC ATCGTGTAATGACTGCCACAA 170 18 
D10S1739 CTGGAAAAACAACAGAGGTG GCTGTCTAAATCAAGGAATGTC 239 17 
D10S1680 AGCCTGAGCAACATATCGAA TCCCGAAGCAGAGAGTACCT 217 25 






























































Primer pair forTransforming growth factor beta receptor- 1 (TGFBR1) Gene 
Primer description Primer sequence 
(5’      3’) 


















Primer pair for transforming growth factor beta receptor- 2 (TGFBR2) Gene 
Primer description Primer sequence 
(5’      3’) 

















Primer pair for actin, alpha 2, smooth muscle, aorta (ACTA2) Gene 
Primer description Primer sequence 
(5’      3’) 























Primer pair for myosin heavy chain 11, smooth muscle (MYH11) Gene 
Primer description Primer sequence 
(5’      3’) 




































































































Primer pair for solute carrier family 2, member 10 (SLC2A10) Gene 
Primer description Primer sequence 
(5’      3’) 

















Primer pair for notch 1 (NOTCH1) Gene 
Primer description Primer sequence 
(5’      3’) 










































Appendix 9: KOD XL DNA polymerase, Novagen 
Reaction mix of KOD XL Long-range kit (Novagen) 
Components Volume in each reaction 
(µL) 
Final Concentration 
PCR Buffer (10x) 5 1x 
dNTPs (10mM each) 5 200 µM (each) 
Primer F (10µM) 2 0.4 µM 
Primer R (10µM) 2 0.4 µM 
KOD XL DNA polymerase 1 2.5 U/µL 
Template 10 10 ng/µL 
DMSO 1 3% 
H2O 23.5 Final volume of 50 µL 
 
Thermal Cycling Condition of KOD XL <8kb. Two different thermal cycling conditions 
were applied for target fragment size <6kb and >6kb. 
 
Appendix 10: GoTaq Flexi DNA polymerase, Promega 
Reaction mix of GoTaq
®
 Flexi DNA Polymerase 











Initial Denaturation 94ºC 60s  
Denaturation 94ºC 30s  
Annealing 58, 60, 62 ºC 10s 30 cycles 
Extension 72ºC 360s  
Final extension 72ºC 600s  





dNTP mix (10mM each) 1 200 µM (each) 
Primer F (10µM) 2 0.3 µM 
Primer R (10µM) 2 0.3 µM 
GoTaq
®
 Flexi DNA 
polymerase 
0.5 5 U/µL 
Template 
15 10 ng/µL 
MgCl2 (25mM) 6 3 mM 
H2O 28.5 Final volume of 50 µL 
 
Thermal Cycling Condition of GoTaq Flexi Long Range < 8 kb. 
Appendix 11: Expand LongRange dNTPack, Roche 
Reaction mix of Expand Long-range dNTPack 
Components Volume in each reaction 
(µL) 
Final Concentration 
Expand Buffer ( 5x) 10 1x 
dNTP mix (10mM each) 2.5 500 µM (each) 
Primer F (10µM) 1.5 0.3 µM 
Primer R (10µM) 1.5 0.3 µM 
Enzyme 0.7 5 U/µL 
Template 10 10 ng/µL 
MgCl2 (25mM) 4 2 Mm 
H2O 19.8 Final volume of 50 µL 
 
Initial Denaturation 95ºC 120s  
Denaturation 95ºC 30s  
Annealing 58,62ºC 30s 30 cycles 
Extension 72ºC 480s  
Final extension 72ºC 300s  





Thermal Cycling Condition for Expand dNTPack Long-Range < 8 kb 





First Cycling 92ºC 120s  
Second Cycling    
Denaturation 92ºC 10s  
Annealing 58, 60, 62ºC 15s 10 cycles 
Extension 68ºC 780s  
Third Cycling    
Denaturation 92ºC 10s  
Annealing 58, 60, 62ºC 15s 20 cycles 
¥
Extension 68ºC 780s  
Final Elongation 68ºC 420s  
Holding 4ºC ∞  
First Cycling 92ºC 120s  
Second Cycling    
Denaturation 92ºC 10s  
Annealing 60 ,62, 64ºC 15s 10 cycles 
Extension 68ºC 780s  
Third Cycling    
Denaturation 92ºC 10s  
Annealing 60 ,62, 64ºC 15s 20 cycles 
¥
Extension 68ºC 780s  
Final Elongation 68ºC 420s  





Appendix 12: Qiagen LongRange PCR, Qiagen 
 
Thermal Cycling Condition for Qiagen LongRange PCR (fragments <5kb) 
Reaction mix of one 50µL long range PCR reaction.*Q-soltution was not added for PCR 
fragments >5kb. 
Components Volume in Each Reaction 
(µL) 
Final Concentration 
PCR Buffer (10x) 5 1x 
dNTPs (10mM each) 2.5 500 µM 
Primer F (10µM) 2 0.4 µM 
Primer R (10µM) 2 0.4 µM 
LongRange PCR Enzyme 
Mix  
0.4 2 U/50µL 
Template 5 10 ng/µL 
*Q-solution (5x) 10 1x 
RNAse free water 
23.1µL (with Q-solution)             OR              33.1 µL (without Q-solution) 
to a final volume of 50 µL 
Initial Denaturation 93ºC 180s  
Denaturation 93ºC 30s  
Annealing 58,64ºC 30s 35 cycles 
Extension 68ºC 30s  
Final extension 68ºC 480s  
Holding 4ºC ∞  
First Cycling 93ºC 180s  
Second Cycling    
Denaturation 92ºC 30s  
Annealing 62ºC 30s 10 cycles 





Thermal Cycling Condition for Qiagen LongRange PCR (fragments > 5 kb). 
¥
Three 
system of thermal cycling condition 
Appendix 13: False variants seen with the “MSFTAAD” 
resequencing assay. 
COL3A1 
6 c.539G>C GC stretch 
8 c.645A>T  
  c.637-16A>T  
20 c.1348-16C>T T stretch 
22 c.1546G>T  
31 c.2134C>A  
43 c.3115C>A  
44 c.3213C>T  
48 c.3531C>A  
50 c.4059T>G wrong primer sequence 
Number 
 of variants 10  
FBN1 
8 c.867T>G  
14 c.1719G>T  
11 c.1415G>A wrong ENSEMBL sequence 
23 c.2729-8C>T  
  c.3589+31T>C Tstretch 
31 c.3839-19T>N  
  c.3829-20A>N  
51 c.6348G>A  
65 c.*33A>G AG stretch 
Number 
 of variants 9  
TGFBR1 
4 c.805+29A>N T stretch 
9 c.1387-14A>N Poly A tail 
Number 
 of variants 2  
MYH11 
1 c.-110-6G>A  
Third Cycling    
Denaturation 92ºC 30s  
Annealing 62ºC 30s 28 cycles 
¥
Extension 72ºC      780s + increment 
of 20s in each cycle 
 






homozygous change in the 
neighbouring position 
21 C stretch  
24 c.2997+29C>T  
31 c.4116+6T>A  
38 c.5172-11C>A  
Number 
 of variants 5  
NOTCH1 
1 c.-76-26C>A  
  c.-76-5A>C  
3 c.335G>A  
4 c.682C>A  
6 c.1027G>A  
10 c.1556-12C>G  
  c.1604C>G  
11 c.1840C>A  
  c.1845G>A  
13 c.2063A>G  
  c.2064C>G  
  c.2081A>T  
15 c.2467+30G>A primer sequence wrong? 
18 c.2761T>A  
  c.2876A>C  
19 c.2996T>A  
  c.3137C>G primer sequence wrong? 
  c.3476T>A  
  c.3171+36G>T  
21 c.3476C>A  
22 c.3579G>C  
29 c.5472+39A>T  
34 c.6549C>T  
  c.6844A>T  
  c.6862T>A  
Number  
of variants 25  
SLC2A10 
1 c.-177G>T  
2 c.170G>T  
Number  
of variants 2  
Total 
number of 







Appendix 14: Topography of known and novel point mutations found with MFSTAAD 
resequencing assay. Schematic representation of proteins fibrillin-1, notch1, myosin alpha, 
heavy chain 11, collagen type III, alpha 1, and genes ACTA2 (top left) SLC2A10 (top right) 
and TGFBR2 (bottom left) with the location of point mutations.  
§
DNA variants with very low 


















Appendix 15: Segregation analysis of DNA variant MYH11 c.4673C>T, p.T1158M with 
family members of PD7. Round symbols indicate females and square symbols indicate 
males. Blackened symbols indicate affected individuals (determined solely by clinical 
information). Black symbols with crossed line indicate a deceased subject. A star beside a 
square or round symbol resembles carriers of this mutation.II:2 PD7 was a 32 years old young 
male who died of sudden and unexplained TAAD. There was no previous clinical history 
reported in the medico-legal autopsy. But the cause of TAAD was highly suspected of a 
heritable disease due to the occurrence of TAAD at young age. Upon mutational analysis of 
TAAD associated genes, a PDC mutation in the gene MYH11 c.4673C>T, p.T1158M was 
found. Two out of three biometric programs such as Pmut and PP2 assigned this DNA 
substitution as possibly damaging with p-scores of 0.65 and 0.90, respectively, whereby MT 
called this change as a polymorphism with a p-score of 0.89. The same mutation was found in 
the father (I:1) of the deceased subject upon mutation segregation analysis. The clinical 
history of the living father suggested the presence of aortic aneurysm, thus indicating that this 
























Appendix 16: Segregation analysis of DNA variant FBN1 c.3509G>A, p.R1170H in 
family members of PD11. Round symbols indicate females and square symbols indicate 
males. Black symbols indicate affected individuals. Black symbols with crossed line indicate 
a deceased subject. A star beside a square or round symbol resembles carriers of this 
mutation. This DNA variant was firstly described by Hayward et al., 1994 who presented two 
related subjects with marfanoid phenotype who did not fulfil the clinical criteria for MFS. 
Only skeletal abnormality more specifically arachnodactyly was observed. Similar 
observations were described in the study of Robinson et al., The same mutation was found in 
PD11, but solely presented with TAAD, a major cardiovascular manifestation of MFS. 
Clinical pre-history included only longstanding hypertension. This sequence alteration was 
assigned as disease-causing by Pmut and MT with p-scores of 0.63 and 0.56, respectively, 
whereby PP2 called this change as benign giving a p-score of 0.01. Co-segregation analysis of 
this PDC mutation and disease was not observed since several family members such as I: 1, 
II:1, 3, 4 and III:1 and 2 appeared normal. Therefore, the mutation in the gene FBN1 





















Appendix 17: Segregation analysis of DNA variant COL3A1 c.217G>C, p.D73H in 
family members of PD15. Round symbols indicate females and square symbols indicate 
males. Black symbols indicate affected individuals. Black symbols with crossed line indicate 
a deceased subject. A star beside a square or round symbol resembles carriers of this 
mutation. A possibly novel disease-causing mutation in the gene COL3A1 c.217G>C, p.D73H 
was detected in PD15, a 42 years old male by whom no previous clinical history was 
recorded. A phenomenon of mild scoliosis was observed in the medico-legal investigation, a 
classic skeletal abnormality seen in MFS patients. This individual died of sudden, 
unexplained TAAD of the ascending aorta. The same genetic change COL3A1 p.D73H 
(c.217G>C) was observed in the father (I: 1), but he had no clinical history for thoracic aortic 
aneurysms. Thus, indicating that this mutation may not be the causative change for TAAD in 
PD15. Whereby, two biometric mutation analysis programs MT and PP2 called the mutation 
COL3A1 p.D73H (c.217G>C) as probably damaging with high scores (p-scores of 0.91 (MT) 






















Appendix 18: Segregation of DNA variant NOTCH1 c.2734C>T, p.R912W in family 
members of RL4. Round symbols indicate females and square symbols indicate males. 
Blackened symbols indicate affected individuals. Blackened symbols with crossed line 
indicate a deceased subject. *Resembles carriers of this mutation. A novel PDC mutation in 
the gene NOTCH1 c.2734C>T, p.R912W has been found in the living Proband RL4. This 
individual was suspected for MFS, because of his classic skeletal abnormality of MFS 
including dolichostenomelia, mild scoliosis and his body height (212cm). Clinical records 
indicated the occurrence of spontaneous pneumothorax twice. The routine genetic testing was 
negative for mutations in the genes FBN1, TGFBR1 and TGFBR2 using the conventional 
Sanger sequencing. Upon subsequent mutation analysis of additional TAAD associated genes, 
a PDC mutation in the gene NOTCH1 c.2734C>T, p.R912W has been found using the 
MFSTAAD resequencing protocol. All three biometric programs showed a severity score close 
to 1 including Pmut (p-score of 0.90), MT (p-score of 0.70) and PP2 (p-score of 0.85). Same 
mutation was detected in the mother (I:2) of RL4, by whom no clinical signs were described 
except for longstanding hypertension (I:2). Whereby, the father (I:1) of RL4 who had multiple 
close relatives with skeletal abnormality for classic MFS was rather negative for mutations in 





















Appendix 19: Segregation analysis of DNA variant MYH11 c.5676G>C, p.E1892D in 
family members of RL6. Round symbols indicate females and square symbols indicate 
males. Blackened symbols indicate affected individuals. *Resembles carriers of this mutation. 
Marfan syndrome was suspected in II:1, however no mutation was detected in the gene FBN1, 
including TGFBR1 and TGFBR2 genes using conventional Sanger sequencing. Subsequent 
mutation analysis of eight TAAD candidate genes, the PDC mutation in the gene MYH11 
c.5676G>C, p.E1892D was found in RL6. Two biometric mutation analysis programs MT 
and PP2 called the mutation MYH11 c.5676G>C, p.E1892D as probably damaging with 
convincing severity scores (p-scores of 1.00 (MT) and 0.77 (PP2)). Similarly, II:2 and II:4 
were also highly suspected for MFS with TAAD. Both of these individuals presented skeletal 
abnormalities and cardiovascular manifestations such as dilatation of the aortic root and aortic 
valve insufficiency. However, the dilatation remained within the normal diameter of 4.7cm. 
Furthermore, individuals II:3 and II:5, had prolonged hypertension, by which II:5 carried the 
PDC mutation, by which no clinical phenotypes for MFS and/or TAAD were described. 
These results indicate that this particular PDC mutation is possibly not the only DNA variant 
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I:1 I:2 


















Appendix 20: Deletion breakpoint characterization by Array CGH. (Top left) Breakpoint 
characterization of deletion Exons 1-65 of the FBN1 Gene, and genes DUT, SLC12A1, 
CTXN2, MYE2 and SLC24A5. (Top right) Breakpoint characterization of Exons 6-65 of the 
FBN1 gene and DUT gene. (bottom left) Breakpoint characterization of deletion Exons 64-65 
of the FBN1 gene. The final data of aCGH was then used as a reference point to derive 
genomic sequence of three of 60-mer oligonucleotide probes from the UCSC genome 
browser. Two of which encompassing the deleted region in the 3’ and 5’ direction and one 
probe positioned on the suspected breaking site of the unique deletion by aCGH. The 
chromosomal location of each of these probes has been used to design primer pairs for PCR 











Appendix 22: Probe information of deletion Exons 6-65 of the gene FBN1 and DUT gene 
























Appendix 21: Probe information of deletion Exons 1-65 of the gene FBN1, genes DUT, 
SLC12A1,CTXN2, MYE2 and SLC24A5 







































































Appendix 23: Probe information of Exons 64-65 deletion of the FBN1 gene 













































Appendix 24: Primer pairs used for deletion breakpoint characterization 
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